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abstract

PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced
prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this
guideline is intended to outline techniques available and provide recommendations on appropriate use of
imaging for speciﬁed patient subgroups.

ASSOCIATED
CONTENT
Appendix
Author afﬁliations
and support
information (if
applicable) appear
at the end of this
article.

METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology,
American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological
Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic
review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced
prostate cancer. Representative index cases of various prostate cancer disease states are presented, including
suspected high-risk disease, newly diagnosed treatment-naı̈ve metastatic disease, suspected recurrent disease
after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the
literature from 2013 to August 2018 identiﬁed fully published English-language systematic reviews with or
without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared $ 2
imaging modalities, and noncomparative studies that reported on the efﬁcacy of a single imaging modality.
RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews
with or without meta-analysis and 18 primary research articles.

Accepted on October
25, 2019 and
published at
ascopubs.org/journal/
jco on January 15,
2020: DOI https://doi.
org/10.1200/JCO.19.
02757

RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced
prostate cancer: conventional imaging (deﬁned as computed tomography [CT], bone scan, and/or prostate
magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography
[PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.

With panel
representation from
the American College
of Radiology,
American Urological
Association, Society
of Abdominal
Radiology, Society of
Nuclear Medicine
and Molecular
Imaging, and the
Society of Urologic
Oncology.
At the time of
publication, this
ASCO Guideline has
been endorsed by the
American College of
Radiology.

INTRODUCTION

J Clin Oncol 38. © 2020 by American Society of Clinical Oncology

The purpose of this clinical practice guideline is to
provide referring and imaging clinicians (including
medical oncologists, radiation oncologists, urologists,
radiologists, nuclear medicine physicians, and molecular imagers), other health care practitioners, patients, and caregivers with recommendations and
future directions regarding optimum imaging for patients with advanced prostate cancer based on the
best available evidence. The ﬂuid and rapidly evolving
nature of the topic is acknowledged, and although
regulatory approvals of some of the techniques presented are currently limited, this guideline is intended
to preemptively address the ongoing barrage of studies
that will most certainly transform the landscape for the

management of patients with advanced prostate
cancer. The term advanced prostate cancer encompasses a wide swath of patients with different disease
states and clinicopathologic factors, including men
with localized prostate cancer at initial diagnosis with
a high or very high risk of metastasis (as deﬁned recently in an American Urological Association/American
Society of Radiation Oncology/Society of Urologic Oncology guideline1); men who have been treated and
subsequently present with clinical, biochemical, or radiographic evidence of disease progression; and men
with known metastatic disease either at initial presentation or after one or more lines of treatment. This
guideline examines the optimal use of imaging for men
in each of these disease states.
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THE BOTTOM LINE
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Endorsed by the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular
Imaging, American Urological Association, American Society for Radiation Oncology, and the Society of Urologic Oncology.
Guideline Question
What are the optimum imaging options that should be offered to patients with advanced prostate cancer?
Target Population
Men with advanced prostate cancer, including newly diagnosed clinical high-risk disease, suspected or conﬁrmed metastatic
disease, recurrent disease, or progressive disease while under treatment.
Target Audience
Medical oncologists, radiation oncologists, urologists, radiologists, nuclear medicine and molecular imaging physicians, other
health care practitioners such as nurses and social workers, patients, and caregivers.
Methods
An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the
medical literature.
Deﬁnitions
•
•
•
•

Conventional imaging: computed tomography (CT), bone scan, and/or prostate magnetic resonance imaging (MRI).
Next-generation imaging (NGI): positron emission tomography (PET), PET/CT, PET/MRI, whole-body MRI.
Advanced prostate cancer: disease states/clinical scenarios described.
Biochemical recurrence: detectable prostate-speciﬁc antigen (PSA) with a subsequent rise after radical prostatectomy or a rise of 2 above nadir PSA achieved after radiotherapy (Phoenix criteria)15; high risk without evidence of
disease locally or distantly on conventional imaging where the deﬁnition of undetectable PSA is dependent on the
assay used and may change over time as more-sensitive assays become available; in general, a PSA value , 0.2 ng/mL
has been considered undetectable,1 while lower values (PSA # 0.01 ng/mL) have been advocated when clinically
available.16

Recommendations
Recommendation 1. Imaging is recommended for all patients with advanced prostate cancer. See the recommendation
under clinical question 4 for speciﬁc details according to clinical scenario (Type: evidence based, beneﬁts outweigh
harms; Evidence quality: moderate; Strength of recommendation: strong).
Recommendation 2. One or more of the following imaging modalities should be used for patients with advanced prostate
cancer: conventional imaging (deﬁned as CT, bone scan, and/or prostate MRI) and/or NGI (PET, PET/CT, PET/MRI,
whole-body MRI), according to clinical scenario (Type: evidence based, beneﬁts outweigh harms; Evidence quality:
moderate; Strength of recommendation: strong).
Recommendation 3. It is recommended when choosing an imaging modality that disease states and clinical scenarios as
outlined are taken into consideration, as the imaging modality may guide treatment or change clinical treatment
decisions (Type: evidence based, beneﬁts outweigh harms; Evidence quality: moderate; Strength of recommendation:
strong).
Newly Diagnosed Clinically High-Risk/Very High-Risk Localized Prostate Cancer
Recommendation 4.1. Conventional imaging negative. When conventional imaging (deﬁned as CT, bone scan, and/or
prostate MRI) is negative in patients with a high risk of metastatic disease, NGI (deﬁned as PET, PET/CT, PET/MRI,
whole-body MRI) may add clinical beneﬁt, although prospective data are limited (Type: informal consensus, beneﬁts/
harm ratio uncertain; Evidence quality: weak; Strength of recommendation: moderate).
Recommendation 4.2. Conventional imaging suspicious/equivocal. When conventional imaging is suspicious or equivocal,
NGI may be offered to patients for clariﬁcation of equivocal ﬁndings or detection of additional sites of disease, which
could potentially alter management, although prospective data are limited (Type: informal consensus, beneﬁts/harm
ratio uncertain; Evidence quality: weak; Strength of recommendation: moderate).
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
Rising PSA After Prostatectomy and Negative Conventional Imaging (either initial PSA undetectable with subsequent rise or PSA
never nadirs to undetectable)
Recommendation 4.3. Both disease states are indicative of potentially undetected, residual local, locoregional, or
micrometastatic disease, and imaging options are not distinct or different between these scenarios. The goal of therapy
and the potential use of salvage local therapies in these scenarios should guide the choice of imaging. For men who are
not candidates or are unwilling to receive salvage local or regional therapy, additional NGI should not be offered (Type:
informal consensus, beneﬁts/harms ratio uncertain; Evidence quality: low; Strength of recommendation: moderate).
Recommendation 4.4. For men for whom salvage radiotherapy is contemplated, NGI should be offered (PSMA imaging
[where available]; 11C-choline or 18F-ﬂuciclovine PET/CT; or PET/MRI, whole-body MRI, and/or 18F-NaF PET/CT) as
they have superior disease detection performance characteristics and may alter patient management (Type: evidence
based, beneﬁts outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Rising PSA After Radiotherapy and Negative Conventional Imaging
Recommendation 4.5. For men in whom salvage local or regional therapy is not planned or is inappropriate, there is little
evidence that NGI will alter treatment or prognosis. The role of NGI in this scenario is unclear and should not be offered,
except in the context of an institutional review board–approved clinical trial (Type: informal consensus, beneﬁts/harms
ratio uncertain; Evidence quality: intermediate; Strength of recommendation: moderate).
Recommendation 4.6. For men for whom salvage local or regional therapy (eg, salvage prostatectomy, salvage ablative
therapy, or salvage lymphadenectomy) is contemplated, there is evidence supporting NGI for detection of local and/or
distant sites of disease. Findings on NGI could guide management in this setting (eg, salvage local, systemic or targeted
treatment of metastatic disease, combined local and metastatic therapy). PSMA imaging (where available), 11C-choline
or 18F-ﬂuciclovine PET/CT or PET/MRI, whole-body MRI, and/or 18F-NaF PET/CT have superior disease detection
performance characteristics compared with conventional imaging and alter patient management, although data are
limited (Type: evidence based, beneﬁts outweigh harms; Evidence quality: intermediate; Strength of recommendation:
moderate).
Metastatic Prostate Cancer at Initial Diagnosis or After Initial Treatment, Hormone Sensitive
Recommendation 4.7. In the initial evaluation of men presenting with hormone-sensitive disease with demonstrable
metastatic disease on conventional imaging, there is a potential role for NGI to clarify the burden of disease and
potentially shift the treatment intent from multimodality management of oligometastatic disease to systemic anticancer
therapy alone or in combination with targeted therapy for palliative purposes, but prospective data are limited (Type:
informal consensus, beneﬁts/harms ratio uncertain; Evidence quality: intermediate; Strength of recommendation:
moderate).
Nonmetastatic Castration-Resistant Prostate Cancer
Recommendation 4.8. For men with nonmetastatic castration-resistant prostate cancer (CRPC), NGI can be offered only if
a change in the clinical care is contemplated. Assuming patients have received or are ineligible for local salvage
treatment options, NGI may clarify the presence or absence of metastatic disease, but the data on detection capabilities
of NGI in this setting and impact on management are limited (Type: consensus, beneﬁts/harms ratio uncertain;
Evidence quality: weak; Strength of recommendation: moderate).
Metastatic CRPC
Recommendation 4.9. PSA progression. As recommended by the Prostate Cancer Working Group 3 consensus statements,
PSA progression alone for men on treatment of metastatic CRPC should not be the sole reason to change therapy.
Conventional imaging can be used for initial evaluation of PSA progression and should be continued to facilitate
changes/comparisons and serially to assess for development of radiographic progression (Type: informal consensus,
beneﬁts/harms ratio uncertain; Evidence quality: intermediate; Strength of recommendation: strong).
Recommendation 4.10. The use of NGI in this cohort is unclear, with a paucity of prospective data. When a change in
clinical care is contemplated, in an individualized manner, and there is a high clinical suspicion of subclinical
metastasis despite negative conventional imaging, the use of NGI could be contemplated, especially in the setting of
a clinical trial (Type: informal consensus, beneﬁts/harms ratio uncertain; Evidence quality: insufﬁcient; Strength of
recommendation: weak).
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
Recommendation 4.11. Radiographic progression on conventional imaging. In men with metastatic CRPC with clear
evidence of radiographic progression on conventional imaging while on systemic therapy, NGI should not be routinely
offered. NGI may play a role if performed at baseline to facilitate comparison of imaging ﬁndings/extent of progression of
disease (Type: consensus, beneﬁts/harms ratio uncertain; Evidence quality: insufﬁcient; Strength of recommendation:
moderate).
Additional Resources
More information, including a Data Supplement with additional evidence tables, slide sets, and clinical tools and resources, is
available at www.asco.org/genitourinary-cancer-guidelines. The Methodology Manual (available at www.asco.org/guidelinemethodology) provides additional information about the methods used to develop this guideline. Patient information is
available at www.cancer.net.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients
should have the opportunity to participate.

Prostate cancer is the most common nondermatologic
cancer in men. In 2019, it was estimated that there would
be 174,650 new cases in the United States, and in spite of
advances in diagnosis and treatment, an estimated 31,620
deaths would occur.2 In addition to its prevalence, prostate
cancer poses unique challenges, including a distinct
clinical disease state characterized by an elevated serum
prostate-speciﬁc antigen (PSA) consistent with recurrent
disease without ﬁndings of metastases on historically
conventional imaging studies and difﬁculty in monitoring
patients with metastatic bone disease due to the poor test
characteristics of conventional bone imaging. For these
reasons, coupled with increasing evidence for local salvage
therapy or metastasis-directed therapy or increasingly effective systemic therapies that have been shown to be
beneﬁcial ever earlier in the natural history of the disease,
there is great interest in identifying better imaging strategies
to inform the optimum management for patients with advanced prostate cancer.

treated with effective therapy can have paradoxically
worsening scans in the face of response to treatment.3
Standard criteria have been developed to standardize
bone scan interpretation and to distinguish response
from progression.4,5 These semiquantitative criteria have
been shown to be feasible, have demonstrated in prospective studies to correlate with survival, and have been
recognized as clinically relevant to warrant their use by
regulatory authorities for drug approval.6-8 In addition,
quantitative tools for the assessment of bone scan data
have been developed, including the automated bone
scan index (BSI), which represents the total tumor
burden as the fraction of the total skeleton weight.9-11
These quantitative tools improve bone scan interpretation
but are still subject to the relatively poor speciﬁcity of
99m
Tc-MDP in patients with metastatic bone disease, the
inability to detect nodal and visceral metastatic disease,
and the poor ability of 99mTc-MDP and CT or MRI to detect
metastatic disease in patients with early biochemical
recurrence.

The predilection for prostate cancer to metastasize to
bone and lymph nodes requires both bone and soft tissue
imaging techniques to assess for staging and to monitor
for response to therapy and progression of disease.
Conventional standard imaging modalities include
99m
Tc-labeled methylene diphosphonate (99mTc-MDP)
bone scan and computerized tomography (CT) or
magnetic resonance imaging (MRI). The relatively poor
speciﬁcity of 99mTc-MDP relates to the fact that MDP
adsorbs onto the crystalline hydroxyapatite mineral of
bone and is not prostate cancer–speciﬁc, thus providing
only an indirect measure of tumor activity based on
osteoblastic activity in the tumor microenvironment. In
addition, the interpretation of a bone scan is subjective,
relying on manual assessments of lesion number, size,
and intensity. Such subjective assessments are problematic in the setting of clinical trials and lead to difﬁculty
in accurately interpreting treatment effects. Patients

In the same way that molecularly targeted therapies have
transformed decision making of many diseases, advances
in nuclear medicine and molecular imaging are poised to
re-invent the way in which we diagnose, stage, and monitor
response to therapy in patients with prostate cancer. These
next-generation imaging (NGI) modalities promise improved diagnostic accuracy for staging prostate cancer,
especially at lower tumor burdens. New radiopharmaceuticals coupled to prostate cancer–speciﬁc targets, such
as prostate-speciﬁc membrane antigen (PSMA), are deﬁned in this guideline as external domain PSMA-binding
ligands labeled with the positron emission tomography
(PET)–emitters 68Ga and 18F, exclusive of the PSMA antibody capromab pendetide that binds the internal domain of
PSMA. These have demonstrated improvements in the
sensitivity for the detection of metastatic disease and the
monitoring of a treatment effect in patients with advanced

4 © 2020 by American Society of Clinical Oncology

Downloaded from ascopubs.org by Queen's University Belfast on February 3, 2020 from 143.117.193.021
Copyright © 2020 American Society of Clinical Oncology. All rights reserved.

Optimum Imaging Strategies for Advanced Prostate Cancer Guideline

prostate cancer compared with conventional imaging.
The recent US Food and Drug Administration (FDA)
approvals of 11C-choline and 18F-ﬂuciclovine for PET
imaging in men with a suspected prostate cancer recurrence based on an elevated PSA following prior
treatment represent watershed moments in the development of novel imaging tools for advanced prostate
cancer.12
While patients and clinicians may ﬁnd additional imaging,
especially NGI, attractive for advanced prostate cancer in
a variety of clinical states, there are several disadvantages
associated with their use. These NGI modalities are costly
and are not routinely covered by all third-party payers in
the United States. Their routine use could signiﬁcantly
increase overall expenditure for prostate cancer care.
While the NGI modalities have excellent sensitivity to
detect low-burden disease, false-positive results may
lead to incorrect patient management in some patients.
Moreover, the presence of NGI-detected lesions may
trigger additional procedures, imaging modalities, and
invasive biopsies, which carry risks and additional cost in
addition to mental burden and uncertainty for patients.
Figure 1 provides the imaging algorithm for high/very highrisk disease at initial presentation (per National Comprehensive Cancer Network). Figure 2 provides the imaging algorithm for patients with rising PSA after local
treatment.
Another important consideration is concern for the Will
Rogers phenomenon, which may ensue when patients
who are classiﬁed as nonmetastatic with conventional
imaging become reclassiﬁed as metastatic after
NGI. This may alter treatment decisions with unknown
consequences on the overall disease course. 13 The
Will Rogers phenomenon also makes comparison
with historical standards and controls very difﬁcult,
with the risk of artifactual changes in stage-speciﬁc
survival. 14
This guideline addresses the goals of imaging in advanced prostate cancer, considering conventional imaging techniques and newer NGI modalities, as well as
unmet needs, the potential impact of imaging according
to different advanced prostate cancer clinical disease
states, and the type of imaging that is most appropriate in
each scenario. The guideline focuses on appropriate
utility of imaging for advanced prostate cancer and not
on treatment decisions; any discussion of treatment
decisions are given in the context of the impact of imaging on clinical decision making. Evaluation of treatment options and treatment decisions are beyond the
scope of this guideline.
GUIDELINE QUESTIONS
This clinical practice guideline addresses four overarching
clinical questions:

High/very high-risk
disease at initial
presentation (per
NCCN)

Conventional
imaging
(CT, BS, or mpMRI)

Negative/equivocal

Positive conventional
imaging

Consider NGI* (WBMRI, 18F-NaF, or
PSMA PET†)

No indication for
NGI‡

FIG 1. Imaging algorithm for high/very high-risk disease at initial
presentation (per National Comprehensive Cancer Network
[NCCN]). (*) Suspicious ﬁndings on NGI would inﬂuence treatment
decisions in patients with advanced prostate cancer and negative
conventional imaging, opening the scope for multimodality treatment of primary and oligometastatic disease or systemic therapy for
more extensive metastatic states, although prospective data are
limited. (†) There is enthusiasm for the potential added value of
PSMA PET/CT and PET/MRI for the assessment of the local and
metastatic extent of prostate cancer in this context, although PSMA
imaging is not currently FDA approved and should thus be only
performed as part of a clinical trial or other controlled research
setting. (‡) NGI could offer clinical beneﬁt in this scenario by
redeﬁning the true extent of disease and shifting treatment decisions
accordingly, although prospective data in this context are limited.
BS, bone scintigraphy; CT, computed tomography; mpMRI, multiparametric magnetic resonance imaging; NGI, next-generation
imaging; PET, positron emission tomography; PSMA, prostatespeciﬁc membrane antigen; WB, whole body.

1. What is the goal of imaging in advanced prostate
cancer?
2. What imaging techniques are available for imaging
advanced prostate cancer?
3. What are the unmet needs and potential impact of
imaging according to different advanced prostate
cancer disease states?
4. When and what type of imaging is appropriate in each
scenario?
The recommendations are framed according to these
clinical scenarios:
A. Newly diagnosed clinically high-risk/very high-risk
prostate cancer
i. Conventional imaging negative
ii. Conventional imaging suspicious/equivocal
B. Rising PSA after prostatectomy and negative
conventional imaging
i. Initial PSA undetectable with subsequent rise
ii. PSA never nadirs to undetectable

Journal of Clinical Oncology
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Rising PSA after
local treatment

Conventional
imaging negative
for mets

Local therapy
not planned or
inappropriate

No indication
for NGI

Suitable for
salvage local
therapy

Previous radical
prostatectomy

Previous
radiotherapy or
ablation (whole
gland or focal)

Consider NGI where
available* (WB-MRI,
11
C-choline PET,
18
F-fluciclovine PET,
18
F-NaF PET, or
PSMA PET†)

Consider NGI where
available* (WB-MRI,
11
C-choline PET,
18
F-fluciclovine PET,
18
F-NaF PET, or
PSMA PET†)

NGI positive:
Consider biopsy of
accessible lesions

NGI negative

Consider
mpMRI prostate
+/- prostate biopsy

NGI positive

Prostate only

Outside of prostate:
Consider biopsy of
accessible lesions

Consider
mpMRI prostate
+/- prostate biopsy

FIG 2. Imaging algorithm for patients with rising prostate-speciﬁc antigen (PSA) after local treatment. (*) For men for whom salvage local
therapy (e.g. salvage radiation, salvage prostatectomy) is an option, there is evidence supporting the use of NGI to assess local or distant
sites of disease, which may guide therapy away from salvage local therapy if indicative of distant metastatic disease. (†) There is enthusiasm for the potential added value of PSMA PET/CT and PET/MRI for the assessment of the local and metastatic extent of prostate
cancer in this context, although PSMA imaging is not currently FDA approved and should thus be only performed as part of a clinical trial or
other controlled research setting. Mets, metastatic disease; mpMRI, multiparametric magnetic resonance imaging; NGI, next-generation
imaging; PET, positron emission tomography; PSMA, prostate-speciﬁc membrane antigen; WB, whole body.

C. Rising PSA after radiotherapy and negative conventional imaging
D. Metastatic prostate cancer at initial diagnosis or after
treatment, hormone sensitive
E. Nonmetastatic castration-resistant prostate cancer
(CRPC)
F. Metastatic CRPC
i. PSA progression
ii. Radiographic progression on conventional imaging

METHODS
Guideline Development Process
This systematic review–based guideline product was developed by a multidisciplinary Expert Panel comprising
members from all the partner organizations (herein, the
Expert Panel), which included a patient representative and
an ASCO guidelines staff member with health research
methodology expertise (Appendix Table A1, online only).

6 © 2020 by American Society of Clinical Oncology
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The Expert Panel met in person several times as well as via
teleconference and/or webinar and corresponded through
e-mail. Based upon the consideration of the evidence,
the authors were asked to contribute to the development
of the guideline, provide critical review, and ﬁnalize the
guideline recommendations. The guideline recommendations were sent for an open comment period of
2 weeks, allowing the public to review and comment on
the recommendations after submitting a conﬁdentiality
agreement. These comments were taken into consideration while ﬁnalizing the recommendations. Members of the Expert Panel were responsible for reviewing
and approving the penultimate version of guideline,
which was then circulated for external review and
submitted to Journal of Clinical Oncology (JCO) for
editorial review and consideration for publication. All
ASCO guidelines are ultimately reviewed and approved
by the Expert Panel and the ASCO Clinical Practice
Guideline Committee (CPGC) prior to publication. All
funding for the administration of the project was provided by ASCO.
The recommendations were developed by using a systematic review (2013 through September 2017 and then
updated in August 2018) of systematic reviews with or
without meta-analysis, phase III randomized clinical trials
(RCTs), comparative nonrandomized studies, and clinical
experience. Articles reporting on other study designs were
considered if they included outcomes, interventions, or
comparisons unavailable elsewhere. Articles were selected
for inclusion in the systematic review of the evidence based
on the following criteria:

• Population: men with advanced prostate cancer
• Fully published or recent meeting presentations
of English-language systematic reviews with or
without meta-analyses, reports of rigorously conducted phase III RCTs that compared two or more
imaging modalities, and noncomparative studies
that report on the efﬁcacy of a single imaging
modality
• Reported on a minimum number of patients (. 50)
Articles were excluded from the systematic review if they
were (1) meeting abstracts not subsequently published in
peer-reviewed journals; (2) editorials, commentaries, letters, news articles, case reports, or narrative reviews; or (3)
published in a non-English language. The guideline recommendations are crafted, in part, using the Guidelines
Into Decision Support (GLIDES) methodology and accompanying BRIDGE-Wiz software.17 In addition, a guideline implementability review is conducted. Based on the
implementability review, revisions were made to the draft
to clarify recommended actions for clinical practice (see
Data Supplement 5: Implementability Survey Results).
Ratings for the type and strength of recommendation,
evidence, and potential bias are provided with each
recommendation.

Detailed information about the methods used to develop
this guideline is available in the Methodology Manual at
www.asco.org/guideline-methodology. Other information
may be found in the Data Supplement, including the
clinical questions (Data Supplement 1), the search strategy
(Data Supplement 2), the QUORUM diagram (Data
Supplement 3), the study quality assessment (Data Supplement 4A), and the study risk of bias assessment (Data
Supplement 4B).
The ASCO Expert Panel and guidelines staff will work with
co-chairs to keep abreast of any substantive updates to the
guideline. Based on formal review of the emerging literature, ASCO will determine the need to update. This is the
most recent information as of the publication date.
Guideline Disclaimer
The Clinical Practice Guidelines and other guidance
published herein are provided by the American Society of
Clinical Oncology, Inc. (ASCO) to assist providers in clinical
decision making. The information herein should not be
relied upon as being complete or accurate, nor should it be
considered as inclusive of all proper treatments or methods
of care or as a statement of the standard of care. With the
rapid development of scientiﬁc knowledge, new evidence
may emerge between the time information is developed
and when it is published or read. The information is not
continually updated and may not reﬂect the most recent
evidence. The information addresses only the topics speciﬁcally identiﬁed therein and is not applicable to other
interventions, diseases, or stages of diseases. This information does not mandate any particular course of
medical care. Further, the information is not intended to
substitute for the independent professional judgment of the
treating provider, as the information does not account for
individual variation among patients. Recommendations
reﬂect high, moderate, or low conﬁdence that the recommendation reﬂects the net effect of a given course of
action. The use of words like “must,” “must not,” “should,”
and “should not” indicates that a course of action is recommended or not recommended for either most or many
patients, but there is latitude for the treating physician to
select other courses of action in individual cases. In all
cases, the selected course of action should be considered
by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO
provides this information on an “as is” basis and makes no
warranty, expressed or implied, regarding the information.
ASCO speciﬁcally disclaims any warranties of merchantability or ﬁtness for a particular use or purpose. ASCO
assumes no responsibility for any injury or damage to
persons or property arising out of or related to any use of this
information, or for any errors or omissions.
Guideline and Conﬂicts of Interest
The Expert Panel was assembled in accordance with
ASCO’s Conﬂict of Interest Policy Implementation
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for Clinical Practice Guidelines (“Policy,” found at
http://www.asco.org/rwc). All members of the Expert Panel
completed ASCO’s disclosure form, which requires disclosure of ﬁnancial and other interests, including relationships with commercial entities that are reasonably
likely to experience direct regulatory or commercial impact
as a result of promulgation of the guideline. Categories for
disclosure include employment; leadership; stock or other
ownership; honoraria, consulting or advisory role; speaker’s
bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance
with the Policy, the majority of the members of the Expert
Panel did not disclose any relationships constituting
a conﬂict under the Policy.
RESULTS
Evidence Overview
A total of 35 articles comprising 17 systematic reviews18-34
with or without meta-analysis and 18 primary research
articles35-52 met eligibility criteria and form the evidentiary
basis for the guideline recommendations. Table 1 provides
a brief description of each. Other articles were brought in for
discussion purposes as warranted.
Systematic Reviews
The 17 systematic reviews18-34 underwent evaluation of
their pooled results from studies published between 1998
and 2017. Eight reviews19,23,24,26,28,30,32,33 compared various PET radiopharmaceuticals labeled with 18F or 11C;
three reviews18,20,22 reported on 68Ga-PSMA binding ligand
PET alone using various radiopharmaceuticals; two
reviews21,34 compared PET/CT using various radiopharmaceuticals with MRI; two reviews25,31 reported on 68GaPSMA binding ligand PET and MRI alone using various
radiopharmaceuticals; and two27,29 reported on a pooled
analysis that included 11C PET/CT, MRI, bone singlephoton emission computed tomography (SPECT), and
bone scintigraphy with various radiopharmaceuticals.
Eleven of these reviews18,19,21,22,24,25,27-29,32,34 reported on
recurrence, staging, or restaging, ﬁve20,23,26,30,33 reported
on diagnostic utility, and one31 reported on the results of
pooling outcomes related to determining extraprostatic
extension and seminal vesicle involvement. Table 1 provides more detail.
Primary Research Articles
The 18 primary research articles35-52 obtained reported on
studies published between 2014 52 and 2018 35 that
accrued patients between 2007 and 2017 (six
articles38,41,44,47,48,51 did not report on the years the study
was open to accrual). Seven of these articles37,38,44,48-50,52
used a prospective design, and 11 articles35,36,39-43,45-47,51
were retrospective studies. Five of these articles35,36,38,40,43
reported on studies investigating PSMA binding ligand imaged with PET (v other PSMA binding ligands

imaged with PET, histology, or other end points), eight
articles37,39,41,42,45,46,49,51 reported on PSMA binding ligand
with PET imaging modalities compared with PET/CT or
PET/MRI alone, and ﬁve articles44,47,48,50,52 reported on
18
F or 11C PET/CT. As no pooling was performed, studies
that were also included in any of the previously summarized systematic reviews were retained and are reported
on. Table 1 provides more detail.
Study Quality Assessment
Study design aspects related to individual study quality,
strength of evidence, strength of recommendations, and
risk of bias were assessed. Findings were that the evidence
obtained was a representative body of literature that recommendations could be based on. For the systematic
reviews, the risk of bias was lower than that of the primary
articles, mostly due to the study designs used in assessments of diagnostic utility (predominantly retrospective
designs with within-group comparisons). See Data Supplement 4A (Study Quality Assessment, systematic reviews
with or without meta-analysis) and Data Supplement 4B
(Study Risk of Bias Assessment, primary studies) for the
complete results of the quality assessment.
Study Results
Systematic reviews. Seventeen systematic reviews18-34
were obtained, and the main ﬁndings (Table 2) include
the following:

• In a systematic review comprising 56 studies and
7,329 patients published between 2005 and 2015, Liu
et al23 found 18F-ﬂuorocholine (FCH) PET/CT superior
to 11C-choline, 11C-acetate, and 18F-ﬂudeoxyglucose
(FDG) for both sensitivity and speciﬁcity in the initial
detection of prostate cancer.
• Treglia et al,28 in a systematic review comprising 14
studies and 1,869 patients published between 2008
and 2013, found 18F-choline or 11C-choline PET/CT
detection rates were affected by PSA doubling times
and rising PSA velocity, and these two factors should
be taken into account when deciding which patients
are appropriate for restaging with choline PET/CT.
• In a systematic review of 47 studies involving 3,167
patients published between 1998 and 2013, von
Eyben et al26 found either 11C-choline PET/CT or
18
F-choline PET/CT informative for recurrence detection in patients with PSA levels between 1 and
50 ng/mL. Performing either test also resulted in
a change to the treatment plan in 41% of patients (381
of 938), while 25% (101 of 404) experienced a complete PSA response.
• Mohsen et al,30 in a systematic review of 25 studies
(number of patients not reported), reported pooled
sensitivity of 75.1% (95% CI, 69.8% to 79.8%) and
pooled speciﬁcity of 75.8% (95% CI, 72.4% to 78.9%)
in the detection of initial prostate cancer and a pooled
sensitivity of 64% (95% CI, 59% to 69%) and pooled
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No. of Included Studies

47 studies (1998-2013)

18 retrospective and prospective (9 choline 1,102 patients with suspected bone
PET/CT, 3 bone SPECT, 6 MRI, and 12
metastases
BS)

14 articles (2008-2013) on radiolabeled
choline in restaging prostate cancer

von Eyben26

Shen27

Treglia28
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Restaging and recurrence detection

(continued on following page)

1,869 patients with suspected BCR

To detect bone metastases

To compare diagnostic accuracy

75 studies with RP for assessing local
5,681 patients for ECE, 5,677 patients for To detect recurrence
staging, 45 for ECE, 34 for SVI, and 38 for
SVI, and 4,001 patients for overall stage
overall T3 stage detection
T3 detection

de Rooij25

3,167 patients with suspected prostate
cancer (11C-choline [n = 1,798];
18
F-choline [n = 550])

29 diagnostic accuracy cross-sectional
2,686 patients previously treated with
Restaging and recurrence
studies with prospective or retrospective
RT or RP suspected of BCR; any relapse
detection
recruitment; 18 with detection rates
(n = 2,126), local relapse (n = 993),
LN and distant metastases (n =752),
bone metastases (n = 775)

Fanti24

To compare diagnostic
accuracy

1,309 patients, 239 of whom have surgical Restaging
nodal data

To detect recurrence

56 studies (2005-2015) that focused on
3,743 cases and 3,586 healthy controls
investigating the diagnostic performance
for initial detection of prostate cancer
of four PET/CT radiotracers in prostate
cancer

16 studies, 5 of which have surgical
nodal data

251 patients

Liu23

Perera

22

6 mostly prospective studies

Ren21

To detect metastases

18 cohort studies (2006-2015) on BCR in
prostate cancer

von Eyben19
2,219 patients suspected of BCR

15 studies: 7 staging, 9 restaging (1 both), 1,256 patients; staging (n = 203), restaging To compare detection rate,
4 prostate segment localization, and 4
(n =983), prostate segment localization
diagnostic test accuracy, and
pelvic LNI
(n = 116), and pelvic LNI (n = 224)
adverse effects

von Eyben20

Purpose

To detect recurrence
24 clinical trials and retrospective analyses 2,408 patients (min:max, 144:532)
previously treated with RT and/or RP with
(2011-2017) that compared 68Ga-PSMAPET/CT to other tracers or imaging
BCR or were suspected of having
modalities
progressive disease as indicated via other
imaging modalities

No. of Included Patients

Fitzpatrick18

Systematic reviews and meta-analysis

First Author

TABLE 1. Evidence Overview

C-choline v

F-FDG v

C-choline PET v

F-choline or
C-choline PET/CT

11

18

C-choline PET, MRI, bone SPECT, bone
scintigraphy (99mTc-MDPBS)

11

Clinical judgment based on conventional
imaging and follow-up

BS

F-choline PET or v

18

11

MRI including mpMRI

Reference standard for locoregional
recurrence, TRUS-guided biopsy; for
distant metastases seea

C-choline PET and/or PET/CT

11

C-acetate

11

F-FCH v

18

C-choline v

11

18

Ga-PSMA for restaging; sensitivity and
speciﬁcity data available for LNI only

F-FACBC PET/CT
68

18

F-FCH PET/CT

18

11

Ga-PSMA for staging and restaging
(subanalyses for postsurgical and pelvic
LNI)

68

Choline-based tracers

Ga-PSMA v

68

Comparisons

Optimum Imaging Strategies for Advanced Prostate Cancer Guideline

9

10 were pooled from a total of 18 studies
(included if reporting certain outcomes,
certain reference standards, and
sufﬁcient sample size)

16 retrospective and primarily single-center PET/CT studies range: 20-358; MRI range: To detect local recurrence
studies
46-84 to detect local recurrence

Evangelista33

Alfarone34

Prospective phase II trial

Retrospective (2013-2016)

Retrospective (2012-2016)

Freitag39

Einspieler40

Prospective (2013-2016)

Retrospective (2013-2017)

Gofﬁn38

Habl

37

Schmidkonz

36

Schmidkonz35 Retrospective (2013-2017)

Primary studies

19 M-As and 36 SRs (included if reporting 1,555 (M-A) with suspected recurrent
prostate cancer
certain outcomes, certain reference
standards, and sufﬁcient sample size)
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To detect local recurrence

To determine extent of disease prior
to initial treatment

To detect recurrence

To detect recurrence

Staging prior to primary treatment

To determine diagnostic utility

(continued on following page)

118 patients with BCR following RT (EBRT, To detect recurrence
n = 77; brachytherapy, n = 41)

119 patients with BCR following RP

105 (104 evaluable) patients with
intermediate- or high-risk disease prior
to RP or eLND

100 patients with BCR following RP with
or without prior RT

225 patients with BCR

93 patients with prostate cancer

441 (M-A) in the detection of LNI

To detect local or distant metastases

To detect EPE and SVI in prostate cancer

Evangelista32

603 patients for the detection of EPE and
SVI in prostate cancer

7 studies (2008-2013) that investigated
MRI in detection of EPE and SVI in
prostate cancer

To determine the diagnostic utility of
recurrence detection

Staging and restaging

Purpose

Silva31

NR, but included patients with suspected
initial and recurrent prostate cancer

2,293 patients

No. of Included Patients

24

44 (case-control and cohort [prospective
and retrospective]); 29 in M-A

No. of Included Studies

Mohsen30

Umbehr

29

First Author

TABLE 1. Evidence Overview (continued)
Comparisons

F-choline PET or

F-choline PET/CT or

Tc-MIP-1404

Tc-MIP-1404

Tc-MIP-1404 v

Ga-11 PET/CT v

68

99m

Ga PET/CT or

68

99m

99m

PSMA ligand

Ga-11 PET/CT

68

Ga-11-PET/mpMRI

68

PSMA ligand

Histology

PSMA ligand

PET/MRI

PSMA ligand

PSMA ligand

PSMA ligand

F-choline PET/CT or 11C-choline
PET/CT and mpMRI (with DCE or alone)

18

Reference standard pathology or other
common imaging modalities

PET/CT

C-choline PET or

11

18

Reference standard pathology or other
common imaging modalities

PET/CT

C-choline PET or

11

18

1.5-T MRI with endorectal coil

C-acetate PET

11

Reference tests included biopsy, histology
from surgery, CT and/or MRI and/or BS,
and/or clinical follow-up, and/or PSA

Index tests included PET without CT

PET/CT

F-choline PET v

18

C-choline PET v

11

Trabulsi et al

Prospective

Retrospective (2014-2015)

Retrospective (2014-2015)

AkinAkintayo44

Rahbar45

Pﬁster46

Purpose

To detect recurrence

To determine response and tolerability

To measure the change in RT treatment
plan

To detect recurrence

93 (91 evaluable) patients

70 patients with BCR following RP or RT

152 patients with BCR following RP or
EBRT

To detect recurrence

To restage recurrent disease

To detect LNI and distant metastases

119 patients with prostate cancer with BCR To detect local recurrence

100 (89 evaluable) patients to detect
recurrence

To detect recurrence

Ga, (n = 28) to To detect recurrence

68

53 BS-negative patients to detect
recurrence

66 patients: 18F (n = 38);
detect recurrence

82 (74 evaluable) patients with mCRPC

87 patients with BCR following RP

131 patients with BCR following treatment To measure the change in treatment plan
with curative intent; RP (n = 11); surgery,
RT, or both (n = 120)

83 patients with BCR following
prostatectomy

191 patients with BCR following RP or RT To detect recurrence

No. of Included Patients

Ga-11 I&T PET/CT v

68

Ga-11 PET/CT

68

F PET/CT v

F PET/CT v

F PET/CT v

F PET/CT v
In PET/CT

111

18

PSMA ligand

WB-MRI

18

PET/MRI

PSMA ligand

C PET/CT

11

18

CT

18

Histology

F PET/CT v

18

PSMA ligand

PSMA ligand
PET/CT

68

Ga PET/CT

68

Ga PET/CT v

68

Ga-HBED-CC PET/CT v

68

Lu-617 followed by

177

PET/CT (n = 43)

F PET/CT (n = 44, 42 evaluable) v

18

PSMA ligand

Ga-11 HBED-CC PET/CT

68

PSMA ligand

Ga

Ga-11 PET (n = 129) v

F PET (n = 62)

18

PSMA ligand

Comparisons
68

Abbreviations: 68Ga, Gallium-68; BCR, biochemical recurrence; BS, bone scintigraphy; CT, computed tomography; DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; EBRT,
external beam radiotherapy; ECE, extracapsular extension; eLND, extended lymph node dissection; EPE, extraprostatic extension; FACBC, ﬂuciclovine; FCH, ﬂuorocholine; FDG, ﬂudeoxyglucose;
HBED-CC, N,N9-Bis(2-hydroxy-5-[ethylene-b-carboxy]benzyl)ethylenediamine N,N9-diacetic acid; I&T, imaging and therapy; LN, lymph node; LNI, lymph node involvement; M-A, meta-analysis; max,
maximum; mCRPC, metastatic castration-resistant prostate cancer; min, minimum; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; NR, not reported; PET,
positron emission tomography; PMSA, prostate-speciﬁc membrane antigen; PSA, prostate-speciﬁc antigen; RP, radical prostatectomy; RT, radiotherapy; SPECT, single-photon emission computed
tomography; SR, systematic review; SVI, seminal vesicle involvement; TRUS, transrectal ultrasound; WB-MRI, whole-body magnetic resonance imaging.
a
Histopathological ﬁndings on lymphadenectomy or biopsy; composite standard; clinical follow-up $ 12 months for C-choline PET-negative studies.

Schuster

Prospective (2007-2012)

Retrospective

Ceci51

52

Prospective (2011-2014)

Barchetti50

Larbi

Prospective (2012-2013)

Prospective

49

Nanni48

Odewole

Retrospective

Retrospective (2015-2015)

Albisinni43

47

Retrospective (2015-2016)

Retrospective analysis of a prospective
series

No. of Included Studies

Berliner42

Dietlein

41

First Author

TABLE 1. Evidence Overview (continued)
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No. of Included Studies

56 studies that focused on
investigating the
diagnostic performance of
4 choline PET/CT
radiotracers (18F-FDG,
11
C-choline, 18F-FCH,
and 11C-acetate) in
prostate cancer (20052015)

14 articles on radiolabeled
choline in restaging
prostate cancer (20082013)

47 studies (1998-2013)

Liu23

Treglia28

von Eyben26

Initial detection, staging, and restaging

Systematic reviews with or without meta-analysis

First Author

TABLE 2. Results: Systematic Reviews
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C-choline PET/CT

11

F-FCH v

18

C-choline PET/CT v 18F-choline PET/CT or
v BS (clinical judgment based on
conventional imaging and follow-up)

11

F-choline or

18

F-FDG v 11C-choline v
11
C-acetate

18

Comparisons

(continued on following page)

3,167 (1,798 11C-choline;
550 18F-choline) with
suspected prostate cancer

1,869 patients with
suspected BCR

3,743 cases and 3,586
healthy controls for initial
detection of prostate
cancer

No. of Included Patients

DOR, 19.17 (95% CI, 8.39 to 43.79)

LR–, 0.45 (95% CI, 0.28 to 0.73)

LR+, 6.86 (95% CI, 4.23 to 11.12)

NPV, 0.85

PPV, 0.70

Speciﬁcity, 0.92 (95% CI, 0.89 to 0.94)

Sensitivity, 0.59 (95% CI, 0.51 to 0.66)

Detection rate PET/CT using the F-choline tracer compared with
scanning using C-choline as the tracer (334 of 550 [60%] v 828
of 1,798 [46%]; P , .0005, Fisher’s exact test)

PSA dt # 6 months and PSA vel . 1 or . 2 ng/mL/year are
predictive factors in detecting positive results of radiolabeled
choline PET/CT

Pooled detection rate: PSA vel . 2 ng/mL/year, 77% (95% CI,
71 to 82)

Pooled detection rate: PSA vel . 1 ng/mL/year, 71% (95% CI,
66 to 76)

Pooled detection rate: PSA dt # 6 months, 65% (95% CI,
58 to 71)

Pooled detection rate, 58% (95% CI, 55 to 60)

18

F-FDG PET/CT . other 3 (18F-FCH PET/CT had the highest AUC,
0.94 % (95% CI, 0.92 to 0.96), and 18F-FDG had the lowest
AUC, 0.73% (95% CI, 0.69 to 0.77)

AUC of SROC, 0.89% (95% CI, 0.86 to 0.91)

Sensitivity, 0.80% (95% CI, 0.74 to 0.85)

Speciﬁcity, 0.84% (95% CI, 0.77 to 0.89)

Results

Trabulsi et al

15 studies; 7 staging, 9
restaging (1 both), 4
prostate segment
localization, 4 pelvic LNI
comparing 11C-choline
and 18F-FCH and PET/CT

von Eyben20

24 studies examining
11
C-acetate PET imaging
in prostate cancer

No. of Included Studies

44 (case-control and cohort
[prospective and
retrospective]); 29 in M-A

30

Umbehr29

Mohsen

First Author

TABLE 2. Results: Systematic Reviews (continued)
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Comparisons

Ga-HBED-CC for staging and restaging
(subanalyses for postsurgical and pelvic
LNI)

68

C-choline PET v 18F-choline PET v PET/CT
(index tests included PET without CT;
reference tests: biopsy; histology from
surgery; CT and/or MRI and/or BS, and/or
clinical follow-up, and/or PSA)

11

C-acetate PET

11

(continued on following page)

1,256 patients; 203 staging,
983 restaging, 116
prostate segment
localization, 224 pelvic LNI

2,293 patients in the staging
and restaging of prostate
cancer

NR, but included patients
with suspected initial and
recurrent prostate cancer

No. of Included Patients

The detection rates of 11C-choline (30 6 5%) and 18F-FCH (39 6
5%) were not statistically different (P = .26)

Pelvic LNI sensitivity, 61%; speciﬁcity, 97%

Prostate segment localization sensitivity, 70%; speciﬁcity, 84%

Detection rate: 74% staging, 50% restaging, PSA 0.2-0.49 ng/mL;
53% restaging, PSA 0.5-0.99 ng/mL

Restaging patients with biochemical failure after local treatment
with curative intent, per patient (12 studies; n = 1,055): pooled
sensitivity, 85% (95% CI, 79% to 89%); speciﬁcity, 88% (95%
CI, 73% to 95%); DOR, 41.4 (95% CI, 19.7 to 86.8); LR+, 7.06
(95% CI, 3.06 to 16.27); LR–, 0.17 (95% CI, 0.13 to 0.22)

Per lesion (11 studies; n = 5,227): pooled sensitivity, 66% (95%
CI, 56% to 75%); speciﬁcity, 92% (95% CI, 78% to 97%); DOR,
22.7 (95% CI, 8.9 to 58.0), LR+, 8.29 (95% CI, 3.05 to 22.54);
LR–, 0.36 (95% CI, 0.29 to 0.46)

Per patient (10 studies; n = 637): pooled sensitivity, 84% (95% CI,
68% to 93%); speciﬁcity, 79% (95% CI, 53% to 93%); DOR,
20.4 (95% CI, 9.9 to 42.0), LR+, 4.02 (95% CI, 1.73 to 9.31),
LR–, 0.20 (95% CI, 0.11 to 0.37)

M-A outcome category staging patients with proven untreated
prostate cancer:

Patients with PSA relapse: LR+, 1.774 (95% CI, 0.642 to 4.906);
LR–, 0.449 (95% CI, 0.216 to 0.934); DOR, 3.876 (95% CI,
0.607 to 24.755)

Accuracy for evaluation of primary tumor: pooled lesion basis
sensitivity, 75.1 (95% CI, 69.8 to 79.8); speciﬁcity, 75.8 (95%
CI, 72.4 to 78.9); LR+, 2.044 (95% CI, 1.303 to 3.204); LR–,
0.311 (95% CI, 0.156 to 0.619); DOR, 6.712 (95% CI, 4.826 to
9.335)

LN staging: pooled speciﬁcity, 79% (95% CI, 72% to 86%)

Recurrence detection (localization): sensitivity, 64% (95% CI,
59% to 69%); speciﬁcity, 93% (95% CI, 83% to 98%)

LN staging: pooled sensitivity, 73% (95% CI, 54% to 88%)

Primary prostate cancer: pooled sensitivity, 93% (95% CI, 90% to
96%)

Results

Optimum Imaging Strategies for Advanced Prostate Cancer Guideline

13

18 cohort studies on BCR in
prostate cancer (20062015)

19

29 diagnostic accuracy
cross-sectional studies
with prospective or
retrospective recruitment;
18 with detection rates

19 M-As and 36 SRs
(included if reporting
certain outcomes, certain
reference standards, and
sufﬁcient sample size)

Fanti24

Evangelista32

von Eyben

24 clinical trials and
retrospective analyses that
compared 68Ga-PSMA
PET/CT to other tracers or
imaging modalities (20112017)

No. of Included Studies

Fitzpatrick18

Recurrence

First Author

TABLE 2. Results: Systematic Reviews (continued)
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F-FCH PET/CT

18

F-choline PET or 11C-choline PET or
PET/CT (reference standard pathology or
other common imaging modalities)

18

C-choline PET and/or PET/CT (reference
standard: for locoregional recurrence,
TRUS-guided biopsy, for distant
metastasesa)

11

C-choline v

11

Ga HBED-CC PSMA v choline-based
tracers

68

Comparisons

(continued on following page)

1,555 (M-A) with suspected
recurrent prostate cancer

2,686 patients previously
treated with RT or RP,
suspected of BCR, 2,126
any relapse, 993 (local
relapse), 752 (LN and
distant metastases), 775
(bone metastases)

2,219 patients suspected of
BCR

2,408 (min:max, 144:532)
patients previously treated
with RT and/or RP with
BCR or were suspected of
having progressive disease
as indicated via other
imaging modalities

No. of Included Patients

GA-PSMA . choline-based tracers

68

Prostatic fossa relapse: sensitivity, 75.4% (95% CI, 66.9% to
82.6%); speciﬁcity, 82.0% (95% CI, 68.6% to 91.4%); LR+,
2.35 (95% CI, 1.03 to 5.39); LR–, 0.44 (95% CI, 0.26 to 0.74);
DOR, 5.86 (95% CI, 1.81 to 18.94)

Pooled diagnostic accuracies for LN metastases: sensitivity, 100%
(95% CI, 90.5% to 100%); speciﬁcity, 81.8% (95% CI, 48.2%
to 97.7%); LR+, 3.72 (95% CI, 0.98 to 14.17); LR–, 0.03 (95%
CI, 0.05 to 0.23); DOR, 138.5 (95% CI, 11.27 to 1,703.8)

All: sensitivity, 85.6% (95% CI, 82.9% to 88.1%); speciﬁcity,
92.6% (95% CI, 90.1% to 94.6%); LR+, 8.53 (95% CI, 3.62 to
20.09); LR–, 0.17 (95% CI, 0.11 to 0.28); DOR, 62.123 (95%
CI, 24.78 to 155.72)

F-choline: sensitivity, 91.8% (95% CI, 88.0% to 94.7%);
speciﬁcity, 95.6% (95% CI, 91.2% to 98.2%); LR+, 11.75
(95% CI, 1.86 to 74.39); LR–, 0.11 (95% CI, 0.03 to 0.46);
DOR, 132.55 (95% CI, 7.59 to 2,315.5)

18

C-choline: sensitivity, 81.8% (95% CI, 77.9% to 85.2%);
speciﬁcity, 91.4% (95% CI, 88.3% to 93.9%); LR+, 7.19 (95%
CI, 2.59 to 19.99); LR–, 0.20 (95% CI, 0.13 to 0.29); DOR,
53.77 (95% CI, 29.02 to 99.62)

11

Pooled diagnostic accuracies for 11C/18F-choline PET and PET/CT
in all sites of disease:

Bone metastases (n = 8), detection rate, 25% (95% CI, 16 to 34)

Local relapse detection rate (n = 10), 27% (95% CI, 16 to 38);
sensitivity (n = 6), 61% (95% CI, 40 to 80); speciﬁcity, 97%
(95% CI, 87 to 99); detection rate (n = 7), 36% (95% CI, 22 to
50)

Overall detection rate any relapse (n = 18), 62% (95% CI, 53 to
71); sensitivity (n = 12), 89% (95% CI, 83 to 93); speciﬁcity,
89% (95% CI, 73 to 96)

P = .26

18

F-FCH, 39 6 5%

11

C-choline, 30% 6 5%

Detection rates:

SUVmax,

Detection rates: PSA , 0.5 ng/mL, 50%; PSA . 2 ng/mL, 95%

Sensitivity, 33% to 94% (where prostate LNI was detected with
68
GA-PSMA, subsequent nodes detected resulted in a . 90%
sensitivity)

Speciﬁcity, . 99%

Results

Trabulsi et al

34

6 mostly prospective studies

16 retrospective and
primarily single-center
studies

No. of Included Studies

Evangelista

10 were pooled from a total of
18 studies (included if
reporting certain
outcomes, certain
reference standards, and
sufﬁcient sample size)

7 studies that investigated
MRI in detection of EPE
and SVI in prostate cancer
(2008-2013)

Silva31

33

18 retrospective and
prospective (9 choline
PET/CT, 3 bone SPECT, 6
MRI, 12 BS) (1990-2012)

Shen27

Detection of bone metastases, EPE, LNI

Ren21

Alfarone

First Author

TABLE 2. Results: Systematic Reviews (continued)
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C-choline PET/CT or F-choline PET/CT
or PET/CT (reference standard pathology
or other common imaging modalities)

11

1.5-T MRI with endorectal coil

C-choline PET, MRI, bone SPECT,
bone scintigraphy (99mTc-MDPBS)

11

F-FACBC PET/CT

18

11

Comparisons
F-choline PET/CT or C-choline PET/CT
and mpMRI (with DCE or alone)

18

(continued on following page)

441 (M-A) in the detection of
LNI

603 patients for the detection
of EPE and SVI in prostate
cancer

1,102 with suspected bone
metastases

251 patients with suspected
recurrence

1,447 patients (including 23
controls) to detect local
recurrence

No. of Included Patients

PET/CT: sensitivity, 0.43 (95% CI, 0.33 to 0.53); speciﬁcity, 0.95
(95% CI, 0.91 to 0.97); LR+, 6.81 (95% CI, 3.08 to 15.04); LR–,
0.66 (95% CI, 0.45 to 0.95); DOR, 13.07 (95% CI, 4.08 to
41.86)

PET alone: sensitivity, 0.74 (95% CI, 0.55 to 0.88); speciﬁcity,
0.91 (95% CI, 0.83 to 0.96); LR+, 6.22 (95% CI, 0.97 to 39.96);
LR–, 0.37 (95% CI, 0.18 to 0.76); DOR, 17.72 (95% CI, 1.83 to
171.90)

Detection of SVI: speciﬁcity, 0.96; sensitivity, 0.5

MRI for detection of EPE: speciﬁcity, 0.82; sensitivity, 0.49

MRI for detection: speciﬁcity, 0.58; sensitivity, 0.6

Per-patient BS: sensitivity, 0.79 (95% CI, 0.73 to 0.83); speciﬁcity,
0.82 (95% CI, 0.78 to 0.85), DOR, 20.32 (95% CI, 5.53 to
74.60), AUC, 0.8876

Per-patient MRI: sensitivity, 0.95 (95% CI, 0.90 to 0.98);
speciﬁcity, 0.96 (95% CI, 0.92 to 0.98); DOR, 343.16 (95% CI,
111.04 to 1,060.57); AUC, 0.9870

Per-patient PET/CT: sensitivity, 0.87 (95% CI, 0.79 to 0.93);
speciﬁcity, 0.97 (95% CI, 0.93 to 0.99); DOR 150.70 (95% CI,
49.67 to 457.23), AUC, 0.9541

Pooled speciﬁcities: PET/CT, 0.95 (95% CI, 0.94 to 0.97); bone
SPECT, 0.85 (95% CI, 0.80 to 0.90); BS, 0.75 (95% CI, 0.71 to
0.79); DOR, 99.78 (95% CI, 78.16 to 6.21); AUC, 0.9494 (95%
CI, 0.938 to 0.7736)

Bone SPECT, 0.90 (95% CI, 0.86 to 0.93); BS, 0.59 (95% CI, 0.55
to 0.63)

Per-lesion basis,b pooled sensitivities: PET/CT, 0.83 (95% CI, 0.81
to 0.85)

Sensitivity, 88%; speciﬁcity, 67%

mpMRI was superior to PET/CT in detecting local recurrence in
patients with low PSA and with small diameter lesions

Results not pooled, but PET/CT has not demonstrated efﬁcacy in
the detection of local recurrence in patients with low levels of
PSA

Results
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15

25

16 studies, 5 of which have
surgical nodal data

75 studies with RP for
assessing local staging, 45
for ECE, 34 for SVI, and 38
for overall T3 stage
detection

No. of Included Studies

1,309 patients, 239 of whom
have surgical nodal data

5,681 patients for ECE,
5,677 patients for SVI,
4,001 patients for overall
stage T3 detection

No. of Included Patients

Ga-HBED-CC PSMA for restaging;
sensitivity and speciﬁcity data available
for LNI only

68

MRI (DWI, DCE), including mpMRI

Comparisons

LNI (per patient): sensitivity, 86%; speciﬁcity, 86%

LNI (per lesion): sensitivity, 80%; speciﬁcity, 97%

T3 stage detection: sensitivity, 61%; speciﬁcity, 88%

SVI: sensitivity, 58%; speciﬁcity, 96%

ECE: sensitivity, 57%; speciﬁcity, 91%

Results

Abbreviations: 99mTc-MDPBS, 99mTc-methylene diphosphonate bone scintigraphy; AUC, area under the curve; BS, bone scintigraphy; CT, computed tomography; DCE, dynamic contrast-enhanced;
DOR, diagnostic odds ratio; dt, doubling time; DWI, diffusion-weighted imaging; ECE, extracapsular invasion; EPE, extraprostatic extension; FACBC, ﬂuciclovine; FCH, ﬂuorocholine; FDG, ﬂudeoxyglucose;
HBED-CC, N,N9-Bis(2-hydroxy-5-[ethylene-b-carboxy]benzyl)ethylenediamine N,N9-diacetic acid; LN, lymph node; LNI, lymph node involvement; LR–, negative likelihood ratio; LR+, positive likelihood
ratio; M-A, meta-analysis; max, maximum; min, minimum; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; NPV, negative predictive value; PET, positron
emission tomography; PPV, positive predictive value; PSA, prostate-speciﬁc antigen; PSMA, prostate-speciﬁc membrane antigen; RP, radical prostatectomy; RT, radiotherapy; SPECT, single-photon
emission computed tomography; SR, systematic review; SROC, summary receiver operating characteristic; SUVmax, maximum standardized uptake value; SVI, seminal vesicle invasion; vel, velocity.
a
Histopathological ﬁndings on lymphadenectomy or biopsy; composite standard; clinical follow-up $ 12 months for C-choline PET-negative studies.
b
Per patient.

Perera22

de Rooij

First Author

TABLE 2. Results: Systematic Reviews (continued)
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105 (104)

118 (2012-2016)

131 (2015-2015)

Gofﬁn38

Einspieler40

Albisinni43

Habl37

100 (2013-2016)

225 (2013-2017)

Schmidkonz36

PSMA compared
with PET/CT,
PET/MRI, or
PET alone

93 (2013-2017)

No. Evaluated

Schmidkonz35

PSMA studies

First Author

TABLE 3. Results: Primary Studies

Ga-HBED-CC

68

Ga-HBED-CC

68

PSMA ligand 68Ga-HBED-CC
PET/CT compared with
PET/MRI

PSMA ligand
PET/CT

PSMA ligand
PET/CT

PSMA ligand 99mTc-MIP-1404
WB planar and SPECT/CT
compared with MRI
conﬁrmed with histology

PSMA ligand 99mTc-MIP-1404
WB planar and SPECT/CT
compared with histology

PSMA ligand 99mTc-MIP-1404
WB planar and SPECT/CT
compared with histology

Comparisons

NR

NR

NR

NR

NR

82%
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NR

NR

NR

NR

NR

76%

Speciﬁcity

NR

NR

NR

NR

NR

NR

Accuracy

(continued on following page)

Sensitivity

NR

NR

NR

NR

NR

NR

PPV

NR

NR

NR

NR

NR

NR

NPV

Other Outcomes

NR

NR

ADT+ v ADT–:
97.7%, 86.3%
(P = .038)

PSA $ 10 ng/mL:
96.8% (P = .038)

PSA 5 to , 10
ng/mL: 95.3%

PSA 2 to , 5
ng/mL: 81.8%

MRI: 86%

SPECT/CT: 94%

ADT+ v ADT–: 86%
v 71%
(P , .001)

PSA , 2 ng/mL:
54% (95% CI,
0.42 to 0.65)

PSA $ 2 ng/mL:
90% (95% CI,
0.85 to 0.95)

68

Ga
59% of patients had a change
to the RT plan based on 68Ga
PET/CT

43% of patients had a
stage change due to
PET/CT

76% (99 of 131) had a change
to their treatment plan due to
68
Ga results

NR

NR

77% (95% CI, 0.72 NR
to 0.83)

97% (95% CI, 0.91 Interobserver agreement was
to 0.99)
. 96% for prostate cancer

Detection Rate
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17

18

Akin-Akintayo44

87

Ga-HBED-CC

68

F-FACBC PET/CT pre– and
post–radiation treatment
decision

18

PSMA ligand
PET/CT

WB-MRI/DWI

NR

NR

NR

NR

NR

NR

93.1% v
86.9%

NR

NR

NR

Speciﬁcity

NR

NR

NR

91.9% v
82.5% (P
, .05)

NR

NR

NR

Accuracy

(continued on following page)

70

Ceci51

C

96 (2012-2013)

Larbi49

F PET/CT or
PET/CT

66 (38) (2014-2015) PSMA ligand 68Ga-HBED-CC
86.9% v
PET/CT compared with
71.2%
18
F-ﬂuoroethycholine PET/CT
and histology

PSMA ligand 177Lu 617 therapy NR
followed by 68Ga PSMA PET
to conﬁrm PSMA expression

Pﬁster46

NR

82 (2014-2015)

PSMA ligand Ga I&T PET/CT
compared with 68Ga-HBEDCC PET/CT

68

Rahbar45

11

Sensitivity

PSMA ligand Ga PET/CT
NR
compared with 68Ga PET/MRI
and mpMRI

68

Comparisons

83 (2015-2016)

119 (2013-2016)

No. Evaluated

42

Berliner

Freitag

39

First Author

TABLE 3. Results: Primary Studies (continued)

NR

NR

NR

75.7% v
67.3%

NR

NR

NR

PPV

NR

NR

NR

96.6% v
88.8%
(P , .05)

NR

NR

NR

NPV

Ga PET/MRI:
7.6%

81%

PET2: lower PSA
and longer PSA
dt

PET+: higher PSA
and faster PSA
dt

74.2%

NR

NR

NR

Other Outcomes

40.5% of patients experienced
a change in their treatment
plan after 18F PET/CT (P ,
.001)

NR

50% of patients with mCRPC
were oligometastatic

28% of patients with mHNPC
were oligometastatic

NR

64% experienced a PSA
decline (31% experienced
a . 50% decline in PSA)

P . .05 for all PSA NR
levels

P = .004

mpMRI: 15.1%

Ga PET/CT: 7.6% NR

68

Detection Rate
68

Trabulsi et al
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115 (2007-2012)

Schuster52

Comparisons

F-FACBC PET/CT

F-choline PET/CT

In-capromab pendetide
SPECT/CT

111

F-FACBC PET/CT

18

WB-MRI

18

C-choline PET/CT

11

18

F-DCFPyL PET/CT
(n = 62); 68GA-HBED-CC
PET/CT (n = 129)

18

F-FACBC PET/CT v CT

18

Speciﬁcity

Accuracy

PPV

NPV

Detection Rate

Prostatic
bed:
56.7%
EPE: 86.7%

EPE: 10%

EPE: 96.7%

EPE: 55%
Prostatic
bed:
67.2%

Prostatic
bed: 40%

99%

98%

40%

67%

NR

Prostatic
bed:
90.2%

98%

99%

32%

37%

P , .05

PSA 3.5 mg/L

88% v 66%

EPE: 42.9%

Prostatic
bed:
63.7%

EPE: 72.9%

Prostatic
bed:
73.6%

98%

98%

32%

38%

NR

EPE: 50%

Prostatic
bed:
75.9%

EPE: 95.7%

Prostatic
bed:
75.3%

97%

98%

90%

97%

NR

P 5 .3

EPE: 41.9%

Prostatic
bed:
45.9%

EPE: 61.7%

Prostatic
bed:
66.7%

98%

96%

3%

4%

NR

P , .001

NR

NR

NR

NR

P 5 .05

P 5 .32

P , .001

P , .05

43.9% (95% 100% (95% 39.5% (95% 5.7%
CI, 28.5%
CI, 31% to
CI, 24.5%
to 60.3%)
100%)
to 56.5%)

P , .05

11.5% (95% 100% (95%
CI, 3.0% to
CI, 74.7%
31.3%)
to 100%)

P , .05
65.9% (95% 100% (95% 51.7% (95% 22.6%
CI, 49.4%
CI, 69.8%
CI, 32.9%
to 79.9%)
to 100%)
to 70.1%)

P , .05

46.2% (95% 100% (95%
CI, 27.1%
CI, 74.7%
to 66.4%)
to 100%)

P , .05

11.4% (95% 87.5% (95% 35.3% (95% 66.7% (95% 31.1% (95% 7.5%
CI, 3.7% to
CI, 60.4%
CI, 22.4%
CI, 24.1%
CI, 18.6%
27.7%)
to 97.8%)
to 49.9%)
to 94.0%)
to 46.8%)

88.6% (95% 56.3% (95% 78.4% (95% 81.6% (95% 69.2% (95% 58.5%
CI, 72.3%
CI, 30.6%
CI, 64.7%
CI, 65.1%
CI, 38.7%
to 96.3%)
to 79.2%)
to 88.7%)
to 91.7%)
to 89.6%)
v
v
v
v
v

Sensitivity

NR

NR

NR

NR

NR

Other Outcomes

Abbreviations: 177Lu 617, lutetium; 99mTc MIP-1404, 99mTc-trofolastat; ADT–, androgen deprivation therapy not administered; ADT+, androgen deprivation therapy administered; CT, computed
tomography; DCFPyL, N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]ﬂuorobenzyl-L-cysteine; dt, doubling time; DWI, diffusion-weighted imaging; EPE, extraprostatic extension; FACBC, ﬂuciclovine;
HBED-CC, N,N9-Bis(2-hydroxy-5-[ethylene-b-carboxy]benzyl)ethylenediamine N,N9-diacetic acid; I&T, imaging and therapy; mCRPC, metastatic castration-resistant prostate cancer; mHNPC, metastatic
hormone-naı̈ve prostate cancer; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; NR, not reported; PET, positron emission tomography; PET+, PET positive;
PET2, PET negative; PSA, prostate-speciﬁc antigen; PSMA, prostate-speciﬁc membrane antigen; RT, radiotherapy; SPECT, single-photon emission computed tomography; WB, whole body.

152 (2011-2014)

100

191

Extraprostatic (41/53)

Prostatic bed (51/53)

No. Evaluated

Barchetti50

Nanni

48

Dietlein

41

Odewole

47

First Author

TABLE 3. Results: Primary Studies (continued)
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•

•

•

•

•

•

•

•

•

speciﬁcity of 93% (95% CI, 83% to 98%) for the
detection of recurrent disease with 11C-acetate PET. It
also found recurrence detection was higher for patients following surgery and/or radiotherapy and for
patients with PSA at . 1 ng/mL at relapse.
Umbehr et al,29 in a systematic review of 44 studies
including 2,293 patients in which 29 studies were
pooled, found both 11C-choline PET and 18F-choline
PET to be useful in restaging patients with biochemical
recurrence to determine the best treatment plan.
In a systematic review of 15 studies involving 1,256
patients, von Eyben et al20 found 68Ga-PSMA PET/CT
to have utility in the detection of disease recurrence for
patients with rising PSA after radical prostatectomy
with PSA levels , 1.0 ng/mL.
Fitzpatrick et al,18 in a systematic review of 24 studies
involving 2,408 patients, found 68Ga-PSMA PET/CT
associated with good sensitivity (33% to 93%) and
high speciﬁcity (. 99%). The likelihood of detection
was found to increase with rising PSA levels and at low
PSA levels, was greater than that of current choline
tracers. Early detection of recurrence does allow for
changes to any follow-up treatment plan. The authors
note that detection may be affected by tracer trapping,
androgen deprivation therapy (ADT), and levels of
PSMA expression.
In a systematic review of 18 cohort studies involving
2,219 patients, von Eyben et al19 found no difference
in detection rates between 11C-choline PET/CT and
18
F-FCH PET/CT in patients with suspected recurrence
(P = .26).
Fanti et al,24 in a systematic review of 29 diagnostic
studies involving 2,686 patients, found 11C-choline
PET/CT to have high accuracy and good sensitivity
(89%) and speciﬁcity (89%) to detect local and/or
distant recurrence in previously treated patients with
prostate cancer.
In a systematic of review of 19 studies involving 1,555
patients, Evangelista et al32 found both 18F-choline PET
or 11C-choline PET or PET/CT to have high pooled
sensitivity (81.8%; 95% CI, 77.9% to 85.2%) and
speciﬁcity (91.4%; 95% CI, 88.3% to 93.9%) to detect
local and/or distant recurrence in previously treated
patients with prostate cancer.
In a systematic review of 16 studies involving 1,447
patients (including 23 controls), Alfarone et al34 found
multiparametric MRI (mpMRI) superior to 18F-choline
or 11C-choline PET/CT in detecting local recurrence in
patients with low PSA and with small-diameter lesions.
Ren et al,21 in a systematic review of 6 studies involving
251 patients, found 18F-ﬂuciclovine PET/CT to have
high sensitivity (88%) and acceptable speciﬁcity
(67%) to detect prostate cancer recurrence.
Shen et al,27 in a systematic review of 18 studies involving 1,102 patients, found MRI superior to
11
C-choline PET/CT, SPECT, and bone scintigraphy in

•

•

•

•

the detection of bone metastases on a per-patient
basis but found PET/CT to be superior to bone
SPECT and bone scintigraphy on a per-lesion basis,
with a higher diagnostic odds ratio and maximum
sensitivity and speciﬁcity scores (Q*).
In a systematic review of 7 studies involving 603 patients, Silva et al31 found 1.5-T MRI to have low sensitivity (49%) and speciﬁcity (58%) when used for the
diagnosis and staging of prostate cancer but that
speciﬁcity increased when used to determine seminal
vesicle invasion (96%) and extraprostatic extension
(82%), while sensitivity remained low for both (45%
and 49%, respectively).
In a systematic review of 18 studies (10 of which were
pooled) involving 441 patients, Evangelista et al33
found 11C-choline PET/CT or 18F-choline PET/CT to
have low pooled sensitivity (0.43; 95% CI, 0.33 to
0.53) but high speciﬁcity (0.95; 95% CI, 0.91 to 0.97)
in the detection of lymph node metastases prior to
surgery in patients with prostate cancer.
In a systematic review of 75 studies involving 5,681
patients, de Rooij et al25 found MRI (diffusion-weighted
[DW] imaging, dynamic contrast enhanced [DCE]) to
have high speciﬁcity but low sensitivity for staging local
prostate cancer. Use of an endorectal coil demonstrated no increase in detection rates for extracapsular
extension but did demonstrate higher sensitivity for
detecting seminal vesicle involvement.
In a systematic review of 16 studies involving 1,309
patients, Perera et al22 found 68Ga-PSMA PET to have
superior sensitivity and speciﬁcity compared with
choline-based PET imaging options and that rising
PSA values and positive 68Ga-PSMA PET results are
correlated.

Primary research articles. Eighteen primary research
articles35-52 were obtained. Full details are provided in
Table 3:

• Three studies35,36,38 investigated the role of the PSMA
binding ligand 99mTc-MIP-1404 imaged with wholebody planar and SPECT/CT compared with histology,
and one of these38 compared the results of both
against MRI ﬁndings. The detection rates with 99mTcMIP-1404 whole-body planar and SPECT/CT were
found to vary with PSA level in one study,36 with higher
PSA being associated with higher detection rates. In
this same study, ADT was also associated with higher
detection rates (ADT positive, 86%; ADT negative,
71%; P , .001). The study that compared 99mTc-MIP1404 SPECT/CT with MRI found higher detection rates
for SPECT/CT (SPECT/CT, 94%; MRI, 86%).38
• Seven37,39,40,42,43,46,51 studies reported on PSMA
binding ligand 68Ga PET/CT. Two40,43 reported on
PSMA binding ligand 68Ga imaged with PET, and
ﬁve37,39,42,46,51 reported on PSMA binding ligand
68
Ga imaged with PET in comparison with PET/CT,
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PET/MRI, or mpMRI. Einspieler et al,40 in a study of
the PSMA binding ligand 68 Ga imaged with PET/CT,
found that the detection rate increased with both
PSA and with ADT (PSA 2 to , 5 ng/mL, 81.8% v
PSA 5 to , 10 ng/mL, 95.3% v PSA $ 10 ng/mL,
96.8%; P = .038) and ADT (ADT positive, 97.7% v;
ADT negative, 86.3%; P = .038). Two studies 37,43
reported that changes to the treatment plan were
made based on the results, with the study by
Albisinni et al43 reporting changing 76% (99 of 131) of
the planned treatments and the study by Habl et al37
reporting changing the staging of 43% of patients and
59% of patients having a change made to the radiation
treatment plan due to 68Ga-PSMA PET/CT outcomes.
For detection of prostate cancer, the study reported by
Freitag et al39 found equivalent rates between 68GaPSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI (PET/
CT, 7.6%; PET/MRI, 7.6%) but found both to be inferior
to mpMRI (15.1%; P = .004). The two 68Ga-HBED-CC
studies reported by Berliner et al42 and Ceci et al51 both
found that detection rates increased with PSA. For
Berliner et al, this difference was signiﬁcant at all PSA
levels (P , .05), and for Ceci et al, while reporting an
overall detection rate of 74.2%, having a positive PET
scan was associated with higher PSA rates and faster
PSA doubling times, and negative PET scans were
associated with the reverse. Of these 7 studies, only
Pﬁster et al46 reported on measures of diagnostic utility
with 68Ga-HBED-CC being associated with higher
sensitivity (86.9% v 71.2%), speciﬁcity (93.1% v
86.9%), accuracy (91.9% v 82.5%), positive predictive value (PPV; 75.7% v 67.3%), and negative
predictive value (NPV; 96.6% v 88.8%) compared
with 18F-ﬂuoroethylcholine PET/CT, but only accuracy and NPV were statistically different at P , .05.
• One study, reported by Rahbar et al,45 examined radionuclide therapy with the PSMA binding ligand 177Lu
617 followed by 68Ga-PSMA PET to conﬁrm PSMA
expression and found that 64% of patients (53 of 82)
experienced a PSA decline (31% experienced a . 50%
decline in PSA).
• One study, reported by Larbi et al,49 examined wholebody MRI/DW imaging in the detection of oligometastatic disease (deﬁned in that study as # 3 synchronous lesions) for treatment planning and found 28% of
all patients with metastatic and hormone-naive prostate cancer were oligometastatic and that 50% of
patients with metastatic CRPC were oligometastatic.
• Six41,44,47,48,50,52 reported on 18F with various radiotracers against other modalities. The study by AkinAkintayo et al,44 in a comparison of 18F-ﬂuciclovine
PET/CT pre– and post–radiation treatment decision,
reported a detection rate of 81%, while 40.5% of
patients experienced a change in their treatment plan
after PET/CT (P , .001). The study by Odewole et al,47
in a comparison between 18F-ﬂuciclovine PET/CT and

CT alone, reported a detection rate of 77.4% with PET/
CT versus 18.9% with CT alone (P , .05). Five studies
reported on measures of diagnostic utility. The study
by Odewole et al,47 in a comparison between
18
F-ﬂuciclovine PET/CT and CT alone, found signiﬁcantly higher sensitivity, accuracy, PPV, and NPV (all
P , .05) associated with 18F-ﬂuciclovine PET/CT in the
prostate/bed, while CT alone reported signiﬁcantly
higher speciﬁcity in the prostate/bed. For extraprostatic disease, 18F-ﬂuciclovine PET/CT in comparison
with CT alone had signiﬁcantly higher sensitivity and
NPV (P , .05), borderline higher accuracy (P = .05),
and similar high speciﬁcity and PPV of 100%, respectively. The study by Dietlein et al,41 in a comparison between 2 PSMA binding ligands (18F-DCFPyL
PET/CT and 68GA-HBED-CC PET/CT), reported sensitivity of 88% with 18F-DCFPyL PET/CT v 66% with
68
Ga-HBED-CC PET/CT for PSA values , 3.5 mg/L
(P , .05). The study by Nanni et al,48 in a comparison
between 18F-ﬂuciclovine PET/CT and 11C-choline PET/
CT, reported superior sensitivity, speciﬁcity, accuracy,
PPV, and NPV associated with ﬂuciclovine PET/CT
over choline PET/CT (P values not reported). In
a comparison between 18F-choline PET/CT and wholebody MRI, Barchetti et al50 found equivalent sensitivity,
speciﬁcity, accuracy, PPV, and NPV. Schuster et al,52
in a comparison between 18F-ﬂuciclovine PET/CT and
111
In-capromab pendetide SPECT/CT for measures of
diagnostic utility in scans of the prostatic bed and
extraprostatic extension, found 18F-ﬂuciclovine PET/
CT superior to 111In-capromab pendetide SPECT/CT
for sensitivity and accuracy, and without signiﬁcant
differences for speciﬁcity, PPV, and NPV for scans of
the prostatic bed; and found 18F-ﬂuciclovine PET/CT
superior to 111In-capromab pendetide SPECT/CT for
sensitvity, accuracy, PPV, and NPV, and equivalent
high speciﬁcity for scans of extraprostatic extension.
RECOMMENDATIONS
CLINICAL QUESTION 1
What is the goal of imaging in advanced prostate cancer?
Recommendation 1
Imaging is recommended for all patients with advanced
prostate cancer. See the recommendation under clinical
question 4 for speciﬁc details according to clinical scenario
(Type: evidence based, beneﬁts outweigh harms; Evidence
quality: moderate; Strength of recommendation: strong).
Literature review, analysis, and clinical interpretation. All
the evidence obtained in this clinical practice guideline (17
systematic reviews with or without meta-analysis and 18
primary articles) supported the use of imaging in advanced
prostate cancer. The goal of imaging in advanced prostate
cancer is to facilitate the accurate and timely detection and
localization of sites of prostate cancer spread and extent,
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Literature review, analysis, and clinical interpretation. Plain
ﬁlm/CT. Plain ﬁlm radiography relies on the differential
penetration of ionizing radiation (x-rays) through body tissues of variable density to produce a 2-dimensional representation of part of the anatomy. Its use in prostate cancer
is limited, including assessment of questionable bone scan
ﬁndings as a crude measure of bony metastasis, as well as
for rapid assessment of complications (eg, bone fractures,
pneumonia). Although large bone metastases can be visible on plain radiography, the modality plays a limited role in
achieving the presented goals of imaging in advanced
prostate cancer.

of energy released and the time it takes protons to “realign”
with the magnetic ﬁeld once the RF pulse is turned off.
Multiple imaging acquisition parameters can be modiﬁed to
provide different “weighting” of the images (eg, T1, T2
weighting), each providing different degrees of visualization
representing different physical and biologic properties of
tissues. Compared with CT, MRI is particularly useful in the
assessment of the bone marrow, as bone marrow edema
resulting from early seeding of metastatic cancer foci, not
visible on CT, can be depicted on MRI. MR also superbly
delineates the prostatic zonal anatomy not clearly visualized
on other modalities and has thus ﬁrmly established itself as
the imaging tool of choice for the assessment of primary
prostatic tumors, using a multiparametric acquisition approach combining “anatomic” (T1- and T2-weighted) and
“functional” (DW and DCE) sequences. Limitations of MRI
include longer examination times compared with CT (pelvic
MRI typically 20-30 minutes; whole-body MRI approximately twice as long); interpretation expertise not as widely
available; and shortcomings with regard to lymph node
metastases, which also rely heavily on the same morphological features assessed with CT. Due to increasing evidence of gadolinium deposition in normal tissues (eg,
brain) and lack of knowledge of the long-term health implications of this ﬁnding, it is widely advocated that intravenous gadolinium for MRI is only used when potential
beneﬁts outweigh risks.

CT also relies on x-rays but takes advantage of computational postprocessing tools to generate high-resolution
3-dimensional images with exquisite anatomic detail. CT
is extensively used in staging and response assessments of
many cancers. Its main advantages are wide availability
and rapid imaging acquisition (a whole-body scan can be
performed in only a few seconds). The main limitations in
advanced prostate cancer are (1) relatively poor performance for detection of bone metastases, as a substantial
amount of cortical destruction is necessary before bone
lesions are visible on CT, and thus early metastases are not
detected, and (2) limited assessment of lymph node metastases primarily due to heavy reliance on morphologic
features (eg, size, shape, borders). CT is unable to identify
micrometastases in normal-sized nodes and unable to
accurately distinguish enlarged hyperplastic (benign) from
malignant nodes. CT is useful for the assessment of
questionable bone scan ﬁndings by demonstrating benign
conditions (trauma, degenerative changes) that result in
false-positive appearances on bone scan.

Improvements in diagnostic performance for detection of
lymph node metastasis can be obtained by using nomograms that consider the pretest probability based on the risk
status of the primary tumor and local staging information.51
Taken together, the general test performance of morphologic imaging remains limited when histologic correlations
using template lymphadenectomy is used as the standard
of reference; a recent meta-analysis showed a CT scan
sensitivity of 42% (95% CI, 20% to 56%) and speciﬁcity of
82% (95% CI, 80% to 83%), while MRI had a sensitivity of
39% (95% CI, 19% to 56%) and speciﬁcity of 82% (95%
CI, 79% to 83%).52 Thus, morphologic CT and MRI misrepresent nodal status and can misdirect the therapeutic
approach. There have been concerted efforts to improve
metastatic nodal detection test performance, and one
promising technique is ferumoxtran-10–enhanced MRI,
which has been shown to be able to detect microscopic
nodal disease.53 Unfortunately, lack of general commercial
availability and regulatory approval makes this method of
assessment unobtainable for most.

MRI. MRI produces multiplanar images without the need
for potentially harmful ionizing radiation. The strong
magnetic ﬁeld in the bore of an MRI scanner causes
protons (which are naturally abundant in the human body)
to align in its direction. A radiofrequency (RF) pulse is then
applied to “spin” the body’s protons out of equilibrium.
Advanced computational tools are then used to generate
images based on the data collected, including the amount

Bone scintigraphy. Bone scans date back to the 1960s.
Over the course of time, the technique found favor for being
relatively inexpensive and capable of whole-body assessment. It involves administration of a diphosphonate, which
mimics phosphate in bone mineral and adsorbs to areas of
active bone formation, particularly around metastases
where osteoblastic activity is prominent. In some cases, it
can detect lesions not seen by CT.54-56 However, there are

thus contributing to the decision-making process for
treatment planning, follow-up, and response assessment.
CLINICAL QUESTION 2
What imaging techniques are available for imaging advanced prostate cancer?
Recommendation 2
One or more of the following imaging modalities should be
used for patients with advanced prostate cancer: conventional imaging (deﬁned as CT, bone scan, and/or
prostate MRI) and/or NGI (PET, PET/CT, PET/MRI, wholebody MRI), according to clinical scenario (Type: evidence
based, beneﬁts outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).
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numerous disadvantages. As the bone scan images not the
tumor itself but the body’s response to it, new bone formation in response to tumor responding to therapy can
appear as a new lesion (ﬂare response).57,58 As a result,
Prostate Cancer Working Group 3 guidelines require new
bone lesions to be seen on two consecutive scans, and new
lesions to be seen on the second scan, before progression
can be called.4 Although this approach leads to a reliable
diagnosis of bone metastases, there is an inherent delay in
establishing this due to the need for conﬁrmatory scans. It
can also be difﬁcult to quantify disease and therefore track
progression. A quantitative measure of involved bone, the
BSI, has been developed, and correlates with overall survival; however, its validity as a biomarker is still under
study.59 A normal bone scan produces two-dimensional
images; the three-dimensional imaging option, SPECT, is
very slow, only allowing imaging of perhaps one or two
anatomic segments of the body, such as the chest and
abdomen or abdomen and pelvis, over the course of
30 minutes (compare this with a PET scanner, which can
scan the whole body in about 15 to 20 minutes or less).
Finally, of course, a bone scan only examines the bones
and will ignore lymphatic or visceral metastases detected
by CT, MRI, or PET.
There is a large generic body of evidence for the use of bone
scan in prostate cancer. A recent meta-analysis looked
speciﬁcally at the yield of bone scintigraphy in the initial
staging of treatment-naı̈ve prostate cancer, and found
a (relatively low) yield of 3.5% with PSA # 10, 6.9% with 10 ,
PSA # 20, and 41.8% with PSA . 20 over 54 studies.60
Detection rate is similarly 4.1% with Gleason score # 6, 10%
with Gleason score 7, and 28.7% with Gleason score $ 8. This
suggests that the existing practice of using bone scan
speciﬁcally for initial staging of higher-risk patients (and not
using it for lower-risk patients) is sound.
PET and PET/CT. PET/CT with a variety of radiopharmaceuticals has received much attention in oncology over the
past several years in alleviating many of the limitations
of standard imaging methods. The radiopharmaceutical
used in PET consists of a pharmaceutical agent or “tracer”
(with biologic properties [eg, receptor binding] determining
its site of accumulation in the body) labeled with a positron
emitting radioisotope (eg, 18F [absorption half-life [t1/2],
110 minutes], 11C [t1/2, 20 minutes], 68Ga [t1/2, 68 minutes]), which will allow its detection with a PET camera.
FDG labeled with the isotope 18F is the most common PET
radiopharmaceutical used in oncology. FDG accumulation
in tumors is related to elevated glucose metabolism in
malignant tissue. In prostate cancer, the diagnostic performance of FDG PET/CT is highly dependent on the phase
of the disease. Cumulative current evidence suggests
that FDG PET may be useful in the imaging evaluation of
extent and treatment response in metastatic castrationresistant disease61 but not in localized prostate cancer
or in early noncastrate metastatic states. Lipogenesis

radiopharmaceuticals, including 11C-acetate and 18F- or
11
C-labeled choline, have also been investigated relatively
extensively. Most studies, primarily from Europe and Japan,
with choline-based radiotracers have focused on the biochemical recurrence of disease. 11C-choline was approved
in the United States in 2012 for imaging evaluation of men
with biochemical recurrence of prostate cancer after deﬁnitive primary therapy. More recently in 2016, the amino
acid analog PET radiotracer 18F-ﬂuciclovine was also approved in the United States for imaging evaluation of men
with biochemical recurrence of prostate cancer. There are
several other unapproved PET radiotracers that are actively
being investigated in the imaging evaluation of prostate
cancer. Of these radiotracers, those targeting the PSMA
receptor have received much attention with exciting results.
PSMA is a transmembrane protein expressed in the secretory cells of the prostate epithelium as well as nonprostate normal and malignant tissues. In prostate cancer,
the PSMA cleavage of vitamin B9 (folic acid) stimulates
oncogenic signaling through glutamate receptors with
downstream activation of the PI3K-Akt-mTOR signaling
pathway.62 Recent strides in synthesis of small-molecule
inhibitors of PSMA targeting the extracellular epitope of
PSMA have demonstrated major potential utility in targeted
radionuclide imaging and treatment (theranostics) of
metastatic prostate cancer. Most studies have reported on
68
Ga-PSMA-11 (also known as HBED-CC). Other PSMA
binding ligands include 68Ga-PSMA imaging and therapy;
68
Ga-PSMA-617; and more recently, 18F-DCFPyL and
18
F-PSMA-1007.63,64 Studies have generally shown superior diagnostic performance of these radiotracers over other
relevant radiotracers in the clinical settings of intermediateto high-risk primary cancer, biochemical recurrence after
deﬁnitive therapy, and delineation of extent of metastatic
disease and patient eligibility for PSMA-targeted radioligand therapy.22 89-Zr–labeled PSMA-targeting antibodies
and minibodies have also been reported, but practicalities
surrounding their use (eg, serial days uptake required
between administration and imaging) have resulted in their
development being largely restricted to tertiary academic
centers. It must be noted that false-negatives and falsepositives can occur with PSMA PET imaging.65 There is also
literature on proposed procedure guidelines and interpretation and reporting standards.66-70 A number of
studies have reported on the major impact of PSMA PET
imaging on management of patients with prostate cancer,
although the potential inﬂuence on outcome will need
additional investigations.71-73 It is hoped that of the several
PSMA-based imaging agents that have been evaluated, the
most optimal agent will emerge that will become approved,
available, and accessible.
In general, radiocholine may be useful in this clinical setting
when PSA . 2 ng/mL (or PSA , 1 ng/mL if primary Gleason
score was 7or more), PSA doubling time is less than
6 months, or PSA velocity is greater than 2 ng/mL/year.
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Higher serum PSA level during biochemical recurrence is
generally associated with higher detectability on choline
PET, with a pooled sensitivity and speciﬁcity of 80.9% and
84.1%, respectively.74 The diagnostic performance of
18
F-ﬂuciclovine in the detection of potential lesions is
also positively associated with PSA level. In the clinically
relevant low PSA range of , 1 ng/mL in men with biochemical recurrence of prostate cancer after radical
prostatectomy and off hormonal therapy, the detectability of
18
F-ﬂuciclovine PET has been reported to be 21% in
comparison with 14% with 11C-choline.48 However, in
general, these two approved radiotracers appear to be
similar in terms of lesion detectability and positive correlation with serum PSA level in the clinical setting of biochemically recurrent prostate cancer.75
PET/MRI. PET/CT has dominated the molecular imaging
landscape for almost two decades as it combines the sensitivity and speciﬁcity of PET and the anatomic depiction of
CT. PET/MRI devices have been available since 2010 and
have been tried in a broad range of clinical settings. However, in general, they have not provided a distinct advantage
over PET/CT beyond the simultaneous acquisition of diagnostic PET and MRI when both tests are clinically indicated. PET/MRI can be helpful in speciﬁc cases. In theory,
PET/MRI devices have several advantages over PET/CT,
including that MRI provides not only anatomy but also
functional imaging information that could increase the
speciﬁcity of PET ﬁndings, and in several regions, such as
the pelvis and bones, MRI provides additional information
that could help to characterize a lesion with PET uptake.
In the initial diagnosis and biopsy of primary prostate
cancer, numerous studies have documented an advantage
to tumor localization using a combination of PET and MRI
either at separate settings or obtained simultaneously in
PET/MRI scanners.76 The most documented advantage is
found for PSMA PET imaging in which numerous studies
document improvement in detection when combining PET
and MRI,76-81 although similar ﬁndings have been noted with
ﬂuciclovine.82-84 Not all studies are positive, and PET/MRI with
11
C-choline76,85 and one study of PSMA86 showed no advantage to PET/MRI. Occasionally, MRI is negative, but PET,
particularly with PSMA-targeted agents, is positive,78,81 aiding
in diagnosis. On the other hand, PSMA-negative primary
tumor occurs in up to 5%-10%.87 MRI also provides better
evaluation of local staging in high-risk patients, such as
extraprostatic extension or seminal vesicle invasion, than can
PET/CT due to superior spatial and contrast resolution.
In biochemical recurrence, the ability to document sites of
localized recurrence (v nodal or bony disease) is perceived
as a potential advantage for PET/MRI across many
agents.63,76,77,80 Particular beneﬁts of MRI versus CT include absence of clip artifacts from prior node dissections
and absence of streaking artifacts from dense contrast
media within the bladder that can interfere with CT scans.

In metastatic disease, there is a perceived advantage of
whole-body MRI in detecting bone marrow changes76,81
based on the sensitivity of DW-MRI for subtle bone disease
and the high contrast of T1-weighted sequences for bone
marrow replacement. However, few studies of prostate
cancer with PET/MRI have been performed, and so there is
an absence of strong data in this setting. For metastatic
disease, whole-body imaging sequences can add considerable time to the scan. Thus, such whole-body imaging is
limited to one sequence (eg, DW or T2-weighted turbo spin
echo) and/or postcontrast-enhanced MRI, which are the
most time efﬁcient methods of evaluating the bones in
conjunction with PET. However, this causes a signiﬁcant
increase in scanning time. Thus, while the increased sensitivity of MRI for bone lesions could be helpful in patients
with suspected metastatic disease, especially with a negative
CT, clinical trial evidence is not yet available to support this.
The advantages of PET/MRI must be weighed against
multiple disadvantages. The cost of such hybrid devices is
approximately 2-3 times that of a conventional PET/CT.
Cost recovery is more difﬁcult as the scans take longer to
obtain, reducing throughput compared with PET/CT. Additional unresolved issues include the accuracy of standardized
uptake value measurements on PET/MRI compared with PET/
CT. Moreover, it is unclear whether it is vital that MRI and PET
be obtained simultaneously in a PET/MRI hybrid scanner or
can be obtained separately as a PET/CT and a dedicated MRI.
It is possible that a PET/CT and a stand-alone MRI could
be performed and achieve the same advantages without
the cost of an expensive hybrid scanner.85,88
Capromab pendetide. Capromab pendetide is an 111Inlabeled antibody directed against the intracellular epitope of PSMA. It is imaged using SPECT/gamma cameras
and is currently approved for initial staging of high-risk
patients and in localization of recurrence after biochemical
failure. Due to the difﬁculties of antibody imaging (imaging
is slow, occurring 3-5 days after injection, and burdened by
physiologic and generic antibody uptake in the bone
marrow, liver, and spleen) and the poor sensitivity due to
the intracellular localization of the epitope (making it unable
to visualize living cancer cells, particularly in bone), the
study is rarely performed at present. Among the few studies
comparing capromab pendetide directly to other imaging
modalities (no meta-analyses exist), one of 93 patients
found it inferior to the new agent ﬂuciclovine at 10%
sensitivity and 87% speciﬁcity for extraprostatic disease
versus 55% sensitivity and 97% speciﬁcity48 for recurrence. A similar study with 50 patients showed 10%
sensitivity and 100% speciﬁcity versus ﬂuciclovine with
100% sensitivity and speciﬁcity for extraprostatic disease.89
An old study comparing capromab pendetide to FDG PET
and CT showed lower detection rates, although sample size
was very small (n = 21 patients).90
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CLINICAL QUESTION 3
What are the unmet needs and potential impact of imaging
according to different prostate cancer disease states?
Recommendation 3
It is recommended when choosing an imaging modality that
disease states and clinical scenarios as outlined are taken
into consideration, as the imaging modality may guide
treatment or change clinical treatment decisions (Type:
evidence based, beneﬁts outweigh harms; Evidence
quality: moderate; Strength of recommendation: strong).
Literature review, analysis, and clinical interpretation.
Prostate cancer frequently recurs despite negative conventional imaging, presumably partly due to unrecognized
residual disease after treatment or distant metastatic disease. For this reason, there is an unmet need for accurate
diagnosis of metastatic disease for accurate staging, appropriate counseling, and adequate treatment planning for
all stages of the disease. Improved and more accurate
diagnosis of disease outside of the prostate or subclinical
metastatic disease offers the potential to modulate or
change treatment. More accurate staging at initial diagnosis
could inﬂuence the local therapy offered (surgery, radiotherapy, ablation, surveillance, and so on). For initial surgery, imaging can impact planning of nerve-sparing
procedures and help to determine the extent of lymphadenectomy. For radiotherapy, the duration of concurrent
and adjuvant ADT could be impacted as well as the extent
of radiation ﬁeld (whole pelvic to include nodal drainage or
just prostate). At the time of biochemical recurrence after
local therapy, the aggressiveness and targeting of salvage
local therapy could also be impacted. For patients with
advanced disease, the timing of changes in systemic
therapies and the accurate ability to monitor response to
therapy could be impacted by more accurate imaging.
CLINICAL QUESTION 4
When and what type of imaging is appropriate in each
scenario?
Newly Diagnosed Clinically High-Risk/Very High-Risk
Localized Prostate Cancer
Recommendation 4.1. Conventional imaging negative
When conventional imaging (deﬁned as CT, bone scan,
and/or prostate MRI) is negative in patients with a high risk
of metastatic disease, NGI (deﬁned as PET, PET/CT, PET/
MRI, whole-body MRI) may add clinical beneﬁt, although
prospective data are limited (Type: informal consensus,
beneﬁts/harm ratio uncertain; Evidence quality: weak;
Strength of recommendation: moderate).
Recommendation 4.2. Conventional imaging suspicious/
equivocal
When conventional imaging is suspicious or equivocal, NGI
may be offered to patients for clariﬁcation of equivocal
ﬁndings or detection of additional sites of disease, which
could potentially alter management, although prospective

data are limited (Type: informal consensus, beneﬁts/harm
ratio uncertain; Evidence quality: weak; Strength of recommendation: moderate).
Literature review, analysis, and clinical interpretation.
Patients presenting with high-risk, including locally advanced, prostate cancer have a high probability of harboring
metastatic disease. The prevalence of metastases is reported to
be between 30% and 50% of patients, depending on the
sensitivity of the method used for disease detection.91 Metastases are most commonly located within regional pelvic lymph
nodes and in bone, with metastases located at other distant
sites being rare at this stage of the disease.
There is wide geographic variation in the availability of NGI
technologies (whole-body MRI and PET/CT), but when
available, they should be considered in the context of
a clinical trial so that generalizable data can be recorded. For
the detection of metastatic bone disease, the combination of
bone scans and CT perform suboptimally compared with
whole-body MRI and various PET/CT radiopharmaceuticals.92 Systematic analyses, prospective clinical studies, and
meta-analyses have shown comparative test performance of
whole-body MRI to NaF and choline PET/CT for the skeletal
assessments in advanced prostate cancer.27,84 Shen et al27
conducted a meta-analysis of 27 studies in advanced
prostate cancer showing MRI was superior to choline PET/CT
and bone scan for metastasis detection on a per-patient
basis. On a per-patient basis, the pooled sensitivities for bone
disease by using choline PET/CT, whole-body MRI, and
bone scan were 91% (95% CI, 83% to 96%), 97% (95% CI,
91% to 99%), and 79% (95% CI, 73% to 83%), respectively.
The pooled speciﬁcities for bone metastases detection using
choline PET/CT, whole-body MRI, and bone scan were 99%
(95% CI, 93% to 100%), 95% (95% CI, 90% to 97%), and
82% (95% CI, 78% to 85%), respectively. On a per-lesion
analysis, choline PET/CT had a higher diagnostic odds ratio
that exceeded both bone scan and bone SPECT for detecting
bone metastases. A recent meta-analysis also underscored
the usefulness of DW-MRI in detecting bone metastases. Liu
et al93 evaluated 32 studies with 1,507 patients and showed
a pooled sensitivity, speciﬁcity, and area under the curve for
DW-MRI of 95% (95% CI, 90% to 97%), 92% (95% CI, 88%
to 95%), and 0.98, respectively, on a per-patient basis, and
91% (95% CI, 87% to 94%), 94% (95% CI, 90% to 96%),
and 0.97, respectively, on a per-lesion basis. This was recently conﬁrmed by a prospective clinical trial where wholebody MRI was compared with NaF PET/CT.84
Suspicious ﬁndings on NGI would inﬂuence treatment
decisions in patients with advanced prostate cancer and
negative conventional imaging, opening the scope for
multimodality treatment of primary and oligometastatic
disease or systemic therapy for more extensive metastatic
states. When evaluating the results of the meta-analyses,
and indeed in all studies reporting test performance of
imaging studies with any modality, it should be noted that
there are intrinsic veriﬁcation biases that are particularly
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prevalent at lesion-level analyses because it is simply not
possible to obtain histopathology for every bone lesion
detected for ethical/practical clinical reasons. As a result,
most studies use combinations of imaging methods and/or
follow-up as the standards of reference.84,94 Furthermore,
as with all external imaging methods, microscopic metastasis are unlikely to be detected so that true-negative
rates are difﬁcult to ascertain.
When conventional imaging is suspicious or equivocal for
nodal or visceral lesions in castration-sensitive patients at
the highest risk of metastatic disease, there is no clear
consensus or level 1 evidence to support 18F-FDG PET/CT
and should not be routinely offered. Whole-body MRI and
NaF PET/CT may offer clinical beneﬁt in this scenario by
redeﬁning the true extent of disease and shifting treatment
decisions accordingly, although prospective data are limited.95 There is limited experience with other PET and radionuclide agents, such as 18F-ﬂuciclovine and 11C- and
18
F-choline, and they are not FDA approved in this setting.
There is enthusiasm for the potential added value of PSMA
PET/CT and PET/MRI for the assessment of the local and
metastatic extent of prostate cancer in this context,80,96,97
although PSMA imaging is currently not FDA approved and
should thus be only performed as part of clinical trials or
other controlled research settings.
Rising PSA After Prostatectomy and Negative
Conventional Imaging (either initial PSA undetectable
with subsequent rise or PSA never nadirs to undetectable)
Recommendation 4.3
Both disease states are indicative of potentially undetected,
residual local, locoregional, or micrometastatic disease,
and imaging options are not distinct or different between
these scenarios. The goal of therapy and the potential use
of salvage local therapies in these scenarios should guide
the choice of imaging. For men who are not candidates or
are unwilling to receive salvage local or regional therapy,
additional NGI should not be offered (Type: informal consensus, beneﬁts/harms ratio uncertain; Evidence quality: low;
Strength of recommendation: moderate).
Recommendation 4.4
For men for whom salvage radiotherapy is contemplated,
NGI should be offered (PSMA imaging [where available];
11
C-choline or 18F-ﬂuciclovine PET/CT; or PET/MRI, wholebody MRI, and/or 18F-NaF PET/CT) as they have superior
disease detection performance characteristics and may
alter patient management (Type: evidence based, beneﬁts
outweigh harms; Evidence quality: high; Strength of recommendation: strong).
Rising PSA After Radiotherapy and Negative
Conventional Imaging
Recommendation 4.5
For men in whom salvage local or regional therapy is not
planned or is inappropriate, there is little evidence that NGI

will alter treatment or prognosis. The role of NGI in this
scenario is unclear and should not be offered, except in the
context of an institutional review board–approved clinical
trial (Type: informal consensus, beneﬁts/harms ratio uncertain; Evidence quality: intermediate; Strength of recommendation: moderate).
Recommendation 4.6
For men for whom salvage local or regional therapy (eg,
salvage prostatectomy, salvage ablative therapy, or salvage
lymphadenectomy) is contemplated, there is evidence supporting NGI for detection of local and/or distant sites of disease. Findings on NGI could guide management in this setting
(eg, salvage local, systemic or targeted treatment of metastatic
disease, combined local and metastatic therapy). PSMA
imaging (where available), 11C-choline or 18F-ﬂuciclovine PET/
CT or PET/MRI, whole-body MRI, and/or 18F-NaF PET/CT
have superior disease detection performance characteristics
compared with conventional imaging and alter patient
management, although data are limited (Type: evidence
based, beneﬁts outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate).
Metastatic Prostate Cancer at Initial Diagnosis or After
Initial Treatment, Hormone Sensitive
Recommendation 4.7
In the initial evaluation of men presenting with hormonesensitive disease with demonstrable metastatic disease on
conventional imaging, there is a potential role for NGI to
clarify the burden of disease and potentially shift the treatment intent from multimodality management of oligometastatic disease to systemic anticancer therapy alone or in
combination with targeted therapy for palliative purposes,
but prospective data are limited (Type: informal consensus,
beneﬁts/harms ratio uncertain; Evidence quality: intermediate; Strength of recommendation: moderate).
Recommendation 4.8. Nonmetastatic CRPC
For men with nonmetastatic CRPC, NGI can be offered only
if a change in the clinical care is contemplated. Assuming
patients have received or are ineligible for local salvage
treatment options, NGI may clarify the presence or absence
of metastatic disease, but the data on detection capabilities
of NGI in this setting and impact on management are limited
(Type: consensus, beneﬁts/harms ratio uncertain; Evidence
quality: weak; Strength of recommendation: moderate).
Recommendation 4.9. Metastatic CRPC (PSA progression)
As recommended by the Prostate Cancer Working Group 3
consensus statements,98 PSA progression alone for men on
treatment of metastatic CRPC should not be the sole reason
to change therapy. Conventional imaging can be used for
initial evaluation of PSA progression and should be continued
to facilitate changes/comparisons and serially to assess for
development of radiographic progression. (Type: informal
consensus, beneﬁts/harms ratio uncertain; Evidence quality:
intermediate; Strength of recommendation: strong).
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Recommendation 4.10
The use of NGI in this cohort is unclear, with a paucity of
prospective data. When a change in clinical care is contemplated, in an individualized manner, and there is a high
clinical suspicion of subclinical metastasis despite negative
conventional imaging, the use of NGI could be contemplated, especially in the setting of a clinical trial (Type: informal consensus, beneﬁts/harms ratio uncertain; Evidence
quality: insufﬁcient; Strength of recommendation: weak).
Recommendation 4.11. Radiographic progression on conventional imaging
In men with metastatic CRPC with clear evidence of radiographic progression on conventional imaging while on
systemic therapy, NGI should not be routinely offered. NGI
may play a role if performed at baseline to facilitate comparison of imaging ﬁndings/extent of progression of disease
(Type: consensus, beneﬁts/harms ratio uncertain; Evidence quality: insufﬁcient; Strength of recommendation:
moderate).
DISCUSSION
There has been tremendous excitement in the prostate
cancer community for advanced, molecular-based, NGI.
This is driven in large part by the biology of the disease as
well as by the clinical need to accurately stage patients and
assess the burden and extent of disease. Prostate cancer
categorization utilizes the clinical disease states model,
which is determined by tumor characteristics, radiographic
extent of disease, and prior therapies administered, making
accurate imaging paramount. The anatomy of the prostate
in the pelvis, with the very delicate surrounding structures
that control crucial bodily functions (urinary, rectal, and
sexual function), makes accurate assessment of extent of
local disease crucial. For men whose disease is no longer
localized and widespread, aggressive local therapy that will
adversely impact urinary, sexual, and bowel domains could
carry unacceptably high adverse effects with detriment to
quality of life. Conversely, aggressive local therapy that
could offer potential cure may be inappropriately withheld
when conventional clinical parameters, such as PSA or
Gleason score, deem a man high risk, for which NGI could
indicate organ-conﬁned disease without evidence of distant
disease. The availability and clinical utility of PSA, an exquisitely sensitive serum-based tumor marker for prostate
cancer, can add to the complexity of accurately determining the disease state, again highlighting the importance of accurate imaging. Following the disease states
model, we have drafted our recommendations utilizing
common clinical scenarios in the natural history of prostate
cancer treatment, for which appropriate use of imaging can
be categorized.
The primary driver for obtaining imaging should be when
clinicians and patients are at a treatment nexus; therefore,
imaging studies that will not impact or inform treatment

decisions should be minimized. The urge or instinct to
order multiple imaging modalities is common for solid tumor oncology, particularly to accurately assess burden of
disease and risk to the patient. The overuse of imaging,
especially NGI, does carry risks of increased cost, inappropriate ionizing radiation delivery to patients, and the
risk of false-positive ﬁndings, which generate fear and
anxiety for patients and clinicians as well as generate other
unnecessary interventions.
As previously stated, the decision for NGI for patients experiencing biochemical recurrence is predicated on the
potential treatment plan. If no additional salvage therapy,
such as salvage radical prostatectomy, salvage radiotherapy, salvage ablative therapy (eg, cryotherapy, highintensity focused ultrasound therapy), or salvage lymphadenectomy, is planned because of patient concerns or
preference due to potential adverse effects or medical
comorbidities that preclude aggressive therapy, then the
utilization and beneﬁt of NGI is questionable.
In the arena of PET-directed imaging, there are multiple
compounds in use that have been proposed, including
small-molecule agents targeting PSMA as well as amino
acid and fatty acid agents. There is a paucity of comparative
data among these agents, and accurate comparisons between them are limited. This is an area in the future where
prospective comparative studies would clarify the appropriate role and utility of these agents.
Similarly, there have been multiple isotopes in use with
varying half-lives and source generators. These include
primarily 11C, 18F, and 68Ga, with several smaller studies
investigating other isotopes. Comparative studies to assess
the accuracy of imaging different isotopes are also lacking,
and the clinical implementation of speciﬁc isotopes have
been driven mostly by half-life, ease of distribution, and
method of isotope generation. This is another area of opportunity for analysis in the future.
In reviewing the published literature, there is a paucity of
well-designed prospective studies in NGI for prostate
cancer, and this Guideline Panel endeavored to create
a reasonable, evidence-based, malleable framework to
guide the optimal use of imaging in patients with advanced
prostate cancer. As technology evolves and current and
future prospective evaluations of NGI become available, we
expect that these guidelines may require updates or
changes in the future.
The Advanced Prostate Cancer Consensus Conference
2017 guideline99 recommended that imaging be performed
at baseline, PSA nadir, and progression at least in patients
with the usual presentation of metastatic hormone-sensitive
prostate cancer. Imaging should also be performed in
between these dates if there are additional clinical needs.
Additionally, regular imaging monitoring of disease is
recommended if there is a likelihood of aggressive variant
prostate cancer (including small-cell and neuroendocrine)
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when the following clinical/pathologic/imaging features are
present100:

• Exclusively visceral metastases
• Radiographically predominant lytic bone metastases
by plain x-ray or CT scan
• Bulky ($ 5 cm) lymphadenopathy or bulky ($ 5 cm)
high-grade (Gleason $ 8) tumor mass in prostate/
pelvis
• Low PSA (# 10 ng/mL) at initial presentation (prior to
ADT or at symptomatic progression in the castrate
setting) plus high-volume ($ 20) bone metastases
• Presence of neuroendocrine markers on histology or in
serum; marked hypercalcemia
• Raised carcinoembryonic antigen
• Short interval (# 6 months) to androgen-independent
progression following the initiation of hormonal therapy
with or without the presence of neuroendocrine
markers

HEALTH DISPARITIES
Although ASCO clinical practice guidelines represent expert recommendations on the best practices in disease
management to provide the highest level of cancer care, it is
important to note that many patients have limited access to
medical care. Racial and ethnic disparities in health care
contribute signiﬁcantly to this problem in the United States.
Patients with cancer who are members of racial/ethnic
minorities suffer disproportionately from comorbidities,
experience more substantial obstacles to receiving care,
are more likely to be uninsured, and are at greater risk of
receiving care of poor quality than other Americans.102-105
Many other patients lack access to care because of their
geographic location and distance from appropriate treatment facilities. Awareness of these disparities in access to
care should be considered in the context of this clinical
practice guideline, and health care providers should strive
to deliver the highest level of cancer care to these vulnerable populations.

SPECIAL COMMENTARY
The recommendations provided are based on systematic
literature review and do not speciﬁcally address the lack of
universal availability of NGI modalities worldwide. Approval
and payment for many NGI modalities have been hampered in the United States and other countries, both regionally and nationally, with signiﬁcant angst for both
patients and clinicians. This aspect is ﬂuid and evolving,
and availability should be considered when clinicians and
patients pursue speciﬁc NGI modalities. As more evidence
is presented that support the clinical utility of these imaging
modalities, the availability of these tests may widen in the
future.
PATIENT AND CLINICIAN COMMUNICATION
In panel discussions, there was robust discussion about
patient counseling and concerns for false-positive and
false-negative imaging results for conventional imaging as
well as for NGI. It should be acknowledged that improved
sensitivity for detection of low-volume metastatic disease
may not be clinically relevant if there is a high false-positive
rate, with attendant secondary testing, biopsy, and so forth.
Additionally, there was also agreement that patients should
be counseled on the life-long risk of ionizing radiation that
NGI testing, particularly involving CT (eg, PET/CT), carry
with the risk of subsequent malignancies. While perhaps
not relevant for patients with advanced prostate cancer who
have exhausted multiple lines of therapy, this does pertain
to men in earlier disease states. Awareness of these issues
with careful and deliberate communication is recommended between clinicians and patients.
For recommendations and strategies to optimize patientclinician communication, see Patient-Clinician Communication: American Society of Clinical Oncology Consensus
Guideline.101

MULTIPLE CHRONIC CONDITIONS
Creating evidence-based recommendations to inform
treatment of patients with additional chronic conditions,
a situation in which the patient may have two or more such
conditions—referred to as multiple chronic conditions
(MCCs)—is challenging. Patients with MCCs are a complex
and heterogeneous population, making it difﬁcult to account for all of the possible permutations to develop speciﬁc
recommendations for care. In addition, the best available
evidence for treating index conditions, such as cancer, is
often from clinical trials whose study selection criteria may
exclude these patients to avoid potential interaction effects
or confounding of results associated with MCCs. As a result,
the reliability of outcome data from these studies may be
limited, thereby creating constraints for expert groups to
make recommendations for care in this heterogeneous
patient population.
As many patients for whom guideline recommendations
apply present with MCCs, any treatment plan needs to take
into account the complexity and uncertainty created by the
presence of MCCs and highlights the importance of shared
decision making regarding guideline use and implementation. Therefore, in consideration of recommended
care for the target index condition, clinicians should review
all other chronic conditions present in the patient and take
those conditions into account when formulating the treatment and follow-up plan.
For patients with prostate cancer under 65 years of age, the
10 most common comorbidities are (in descending order)
hypertension, hyperlipidemia, diabetes, ischemic heart
disease, anemia, arthritis, chronic kidney disease, depression, chronic obstructive pulmonary disease (COPD),
and heart failure. For patients with prostate cancer over
65 years of age, the 10 most common comorbidities are (in
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descending order) hypertension, hyperlipidemia, ischemic
heart disease, anemia, diabetes, arthritis, chronic kidney
disease, cataract, heart failure, and COPD.
In light of these considerations, practice guidelines should
provide information on how to apply the recommendations
for patients with MCCs, perhaps as a qualifying statement
for recommended care. This may mean that some or all of
the recommended care options are modiﬁed or not applied,
as determined by best practice in consideration of
any MCC.
Men with advanced prostate cancer commonly may have
medical comorbidities and chronic kidney disease, which
preclude the use of iodinated contrast or gadolinium. This
may limit the applicability and administration of conventional and NGI in speciﬁc patient populations. An individualized approach is recommended to account for
these conditions.
COST IMPLICATIONS
There has been a dramatic expansion in health care expenditures over the past 2 decades, and imaging technologies represent one of the fastest growing areas of health
care spending. In particular, advanced imaging technologies, such as MRI, CT, and PET, may drive as much as
50% of these increased costs.106 Policy levers may be able
to control some of these spiraling costs107; however, increasingly, individuals diagnosed with cancer are required
to pay a larger proportion of their treatment costs.108-110
These higher out-of-pocket payments may represent
a barrier to the initiation of and adherence to recommended
cancer treatments.111-113 Therefore, a tailored discussion of
potential diagnostic and treatment costs is an important
component of shared treatment decision making.114 When
feasible, clinicians should counsel patients regarding the
use of less expensive alternatives for diagnosis and treatment when there is clinical equipoise or rapidly evolving
therapy options, such as the case with imaging for advanced prostate cancer.114
Importantly, there is considerable heterogeneity in health
care costs for diagnostic imaging. Variation in expenditure
may be related to region, payer, hospital system, negotiated
contracts, insurance status, or severity of illness, and this
variability precludes a systematic and generalizable evaluation.115 With regard to advanced imaging modalities in
particular, there is substantial variation in organizational
costs related to isotope procurement from external sources
(18F-choline), possible cyclotron expenses (11C-choline),
generator expenses, and radiopharmacy (68Ga-PSMA) as
well as the direct costs of disposable equipment and
indirect costs of physicians, technologists, and radiopharmacists.116 When discussing ﬁnancial issues surrounding care delivery, patients should be made aware of
any economic counseling services available to address
this very complex landscape.114

Given the recent and rapid expansion of imaging modalities
for advanced prostate cancer, there are no exhaustive
comparative effectiveness analyses that encompass each
of the techniques described in this guideline. There are
data that suggest that advanced imaging modalities can
be cost effective for patients with cancer, in general,
particularly when used for monitoring therapy, staging,
or diagnosis, rather than screening.117 A formal costeffectiveness evaluation of advanced imaging for patients
with prostate cancer will have to balance the important
patient-level factors speciﬁcally associated with a prostate
cancer diagnosis, such as the relative longevity associated
with a high-risk prostate cancer diagnosis, the loss of
physical productivity, and the substantial costs associated
with skeletal-related events.118-120
As this ﬁeld continues to rapidly expand and we endeavor to
clarify the most sensitive and cost-effective imaging modality for advanced prostate cancer, it will be important to
consider the potential impact of the inevitable regionalization and the subsequent access challenges that
these emerging, advanced technologies will likely create.
This will be a particularly important consideration for
populations at already increased risk of health care
disparities.
EXTERNAL REVIEW AND OPEN COMMENT
The draft recommendations were released to the public
for open comment from February 22, 2019, through
March 8, 2019. Response categories of “Agree as
written,” “Agree with suggested modiﬁcations,” and
“Disagree. See comments” were captured for every
proposed recommendation, with 13 submissions received. A total of 100% of the 13 respondents either
agreed or agreed with slight modiﬁcations to the recommendations, and 0% of the respondents disagreed.
Expert Panel members reviewed comments from all
sources and determined whether to maintain original
draft recommendations, revise with minor language
changes, or consider major recommendation revisions.
All changes were incorporated prior to CPGC review and
approval.
The draft was submitted to 2 external reviewers with
content expertise. It was rated as high quality, and it was
agreed that it would be useful in practice. Comments received assisted in presenting the strength of the evidence
that supported each of the recommendations and helped to
contextualize this guideline in relation to other ASCO
guidelines within this disease site. Review comments were
reviewed by the Expert Panel and integrated into the ﬁnal
manuscript before approval by the CPGC.
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation
across health settings. Barriers to implementation include the need to increase awareness of the guideline
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recommendations among frontline practitioners and survivors of cancer and caregivers as well as to provide
adequate services in the face of limited resources. The
guideline Bottom Line Box was designed to facilitate
implementation of recommendations. This guideline will be
distributed widely through the ASCO Practice Guideline
Implementation Network. ASCO guidelines are posted on
the ASCO web site and most often published in JCO and
a summary in Journal of Oncology Practice.

PSMA) do not have regulatory approval for use in the
United States.
ADDITIONAL RESOURCES
More information, including a Data Supplement with
additional evidence tables, slide sets, and clinical tools
and resources, is available at www.asco.org/genitourinarycancer-guidelines. Patient information is available at
www.cancer.net.

LIMITATIONS OF THE RESEARCH AND FUTURE RESEARCH
This guideline is based on the best available evidence
regarding the use of imaging in advanced prostate
cancer. However, it is recognized that there are gaps in
knowledge related to insufﬁciency or absence of data in
various scenarios related to this condition. Speciﬁcally,
there are limited data on head-to-head comparisons of
diagnostic performance of different imaging modalities
or different radiopharmaceutical agents in the same
patient population. Also, while there is evidence of
feasibility of use and change in management as a result
of imaging ﬁndings, none of the imaging modalities show
prospective evidence conferring patient beneﬁt in terms
of outcomes (ie, how patients feel, function, or survive).
These should be areas for focused future research. Finally, some of the agents that have been shown to have
higher detection capabilities in prostate cancer (eg,
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